CN1159759A - 含有肿瘤排斥抗原前体或肿瘤排斥抗原以及佐剂和/或生长因子的组合物 - Google Patents
含有肿瘤排斥抗原前体或肿瘤排斥抗原以及佐剂和/或生长因子的组合物 Download PDFInfo
- Publication number
- CN1159759A CN1159759A CN95195411A CN95195411A CN1159759A CN 1159759 A CN1159759 A CN 1159759A CN 95195411 A CN95195411 A CN 95195411A CN 95195411 A CN95195411 A CN 95195411A CN 1159759 A CN1159759 A CN 1159759A
- Authority
- CN
- China
- Prior art keywords
- gag
- ctg
- gaa
- seq
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 105
- 239000000427 antigen Substances 0.000 title claims abstract description 75
- 108091007433 antigens Proteins 0.000 title claims abstract description 72
- 102000036639 antigens Human genes 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000002243 precursor Substances 0.000 title claims abstract description 28
- 239000002671 adjuvant Substances 0.000 title claims abstract description 25
- 239000003102 growth factor Substances 0.000 title claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 12
- 229930182490 saponin Natural products 0.000 claims abstract description 4
- 150000007949 saponins Chemical class 0.000 claims abstract description 4
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims abstract description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims abstract 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims abstract 4
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 230000004044 response Effects 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 241000219287 Saponaria Species 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 36
- 210000004027 cell Anatomy 0.000 abstract description 30
- 230000002163 immunogen Effects 0.000 abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 10
- 230000028993 immune response Effects 0.000 abstract description 3
- 230000005867 T cell response Effects 0.000 abstract description 2
- 108091008875 B cell receptors Proteins 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 57
- 150000001413 amino acids Chemical class 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 37
- 150000007523 nucleic acids Chemical class 0.000 description 35
- 108020004707 nucleic acids Proteins 0.000 description 34
- 102000039446 nucleic acids Human genes 0.000 description 34
- 125000000539 amino acid group Chemical group 0.000 description 33
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 22
- 239000000463 material Substances 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 16
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 9
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 8
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 108010093581 aspartyl-proline Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 4
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 4
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- KZYSHAMXEBPJBD-JRQIVUDYSA-N Asn-Thr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZYSHAMXEBPJBD-JRQIVUDYSA-N 0.000 description 3
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 3
- KHUFDBQXGLEIHC-BZSNNMDCSA-N His-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 KHUFDBQXGLEIHC-BZSNNMDCSA-N 0.000 description 3
- HGNUKGZQASSBKQ-PCBIJLKTSA-N Ile-Asp-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HGNUKGZQASSBKQ-PCBIJLKTSA-N 0.000 description 3
- SXOFUVGLPHCPRQ-KKUMJFAQSA-N Leu-Tyr-Cys Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(O)=O SXOFUVGLPHCPRQ-KKUMJFAQSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102220519838 Putative neutrophil cytosol factor 1B_P91A_mutation Human genes 0.000 description 3
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 3
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 3
- TZNNEYFZZAHLBL-BPUTZDHNSA-N Trp-Arg-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O TZNNEYFZZAHLBL-BPUTZDHNSA-N 0.000 description 3
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108010020688 glycylhistidine Proteins 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 102220023257 rs387907546 Human genes 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 2
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 2
- IJPNNYWHXGADJG-GUBZILKMSA-N Arg-Ala-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O IJPNNYWHXGADJG-GUBZILKMSA-N 0.000 description 2
- PAPSMOYMQDWIOR-AVGNSLFASA-N Arg-Lys-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PAPSMOYMQDWIOR-AVGNSLFASA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 2
- 206010062805 Dysplastic naevus Diseases 0.000 description 2
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 2
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 2
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- YPHPEHMXOYTEQG-LAEOZQHASA-N Glu-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O YPHPEHMXOYTEQG-LAEOZQHASA-N 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- HGFGEMSVBMCFKK-MNXVOIDGSA-N Leu-Ile-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HGFGEMSVBMCFKK-MNXVOIDGSA-N 0.000 description 2
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 2
- GFWLIJDQILOEPP-HSCHXYMDSA-N Lys-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N GFWLIJDQILOEPP-HSCHXYMDSA-N 0.000 description 2
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 2
- SODXFJOPSCXOHE-IHRRRGAJSA-N Met-Leu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O SODXFJOPSCXOHE-IHRRRGAJSA-N 0.000 description 2
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
- HGNGAMWHGGANAU-WHOFXGATSA-N Phe-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HGNGAMWHGGANAU-WHOFXGATSA-N 0.000 description 2
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 2
- XYHMFGGWNOFUOU-QXEWZRGKSA-N Pro-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 XYHMFGGWNOFUOU-QXEWZRGKSA-N 0.000 description 2
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical class NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- GRPHQEMIFDPKOE-HGNGGELXSA-N Ala-His-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GRPHQEMIFDPKOE-HGNGGELXSA-N 0.000 description 1
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GHNDBBVSWOWYII-LPEHRKFASA-N Arg-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GHNDBBVSWOWYII-LPEHRKFASA-N 0.000 description 1
- ZEAYJGRKRUBDOB-GARJFASQSA-N Arg-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZEAYJGRKRUBDOB-GARJFASQSA-N 0.000 description 1
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 1
- KZXPVYVSHUJCEO-ULQDDVLXSA-N Arg-Phe-Lys Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 KZXPVYVSHUJCEO-ULQDDVLXSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 102100024515 GDP-L-fucose synthase Human genes 0.000 description 1
- XEYMBRRKIFYQMF-GUBZILKMSA-N Gln-Asp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XEYMBRRKIFYQMF-GUBZILKMSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
- WVTIBGWZUMJBFY-GUBZILKMSA-N Glu-His-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O WVTIBGWZUMJBFY-GUBZILKMSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- TWYFJOHWGCCRIR-DCAQKATOSA-N Glu-Pro-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYFJOHWGCCRIR-DCAQKATOSA-N 0.000 description 1
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- DNVDEMWIYLVIQU-RCOVLWMOSA-N Gly-Val-Asp Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O DNVDEMWIYLVIQU-RCOVLWMOSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- YXXKBPJEIYFGOD-MGHWNKPDSA-N His-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N YXXKBPJEIYFGOD-MGHWNKPDSA-N 0.000 description 1
- SVVULKPWDBIPCO-BZSNNMDCSA-N His-Phe-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SVVULKPWDBIPCO-BZSNNMDCSA-N 0.000 description 1
- KAXZXLSXFWSNNZ-XVYDVKMFSA-N His-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KAXZXLSXFWSNNZ-XVYDVKMFSA-N 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- FFKJUTZARGRVTH-KKUMJFAQSA-N His-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FFKJUTZARGRVTH-KKUMJFAQSA-N 0.000 description 1
- DMAPKBANYNZHNR-ULQDDVLXSA-N His-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N DMAPKBANYNZHNR-ULQDDVLXSA-N 0.000 description 1
- 101001052793 Homo sapiens GDP-L-fucose synthase Proteins 0.000 description 1
- 101001005716 Homo sapiens Melanoma-associated antigen 11 Proteins 0.000 description 1
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- ZZHGKECPZXPXJF-PCBIJLKTSA-N Ile-Asn-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZZHGKECPZXPXJF-PCBIJLKTSA-N 0.000 description 1
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
- FTUZWJVSNZMLPI-RVMXOQNASA-N Ile-Met-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N FTUZWJVSNZMLPI-RVMXOQNASA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- KGCLIYGPQXUNLO-IUCAKERBSA-N Leu-Gly-Glu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O KGCLIYGPQXUNLO-IUCAKERBSA-N 0.000 description 1
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 1
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 1
- KFSALEZVQJYHCE-AVGNSLFASA-N Lys-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N KFSALEZVQJYHCE-AVGNSLFASA-N 0.000 description 1
- KQBJYJXPZBNEIK-DCAQKATOSA-N Met-Glu-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQBJYJXPZBNEIK-DCAQKATOSA-N 0.000 description 1
- WWWGMQHQSAUXBU-BQBZGAKWSA-N Met-Gly-Asn Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O WWWGMQHQSAUXBU-BQBZGAKWSA-N 0.000 description 1
- PHKBGZKVOJCIMZ-SRVKXCTJSA-N Met-Pro-Arg Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PHKBGZKVOJCIMZ-SRVKXCTJSA-N 0.000 description 1
- ZDJICAUBMUKVEJ-CIUDSAMLSA-N Met-Ser-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O ZDJICAUBMUKVEJ-CIUDSAMLSA-N 0.000 description 1
- 101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 1
- SGCZFWSQERRKBD-BQBZGAKWSA-N Pro-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 SGCZFWSQERRKBD-BQBZGAKWSA-N 0.000 description 1
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 description 1
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000585094 Rattus norvegicus Syntaxin-1B Proteins 0.000 description 1
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 1
- OHKLFYXEOGGGCK-ZLUOBGJFSA-N Ser-Asp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OHKLFYXEOGGGCK-ZLUOBGJFSA-N 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- WBINSDOPZHQPPM-AVGNSLFASA-N Ser-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)O WBINSDOPZHQPPM-AVGNSLFASA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- XNXRTQZTFVMJIJ-DCAQKATOSA-N Ser-Met-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XNXRTQZTFVMJIJ-DCAQKATOSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- LHUBVKCLOVALIA-HJGDQZAQSA-N Thr-Arg-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LHUBVKCLOVALIA-HJGDQZAQSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- GIOBXJSONRQHKQ-RYUDHWBXSA-N Tyr-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O GIOBXJSONRQHKQ-RYUDHWBXSA-N 0.000 description 1
- NMKJPMCEKQHRPD-IRXDYDNUSA-N Tyr-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NMKJPMCEKQHRPD-IRXDYDNUSA-N 0.000 description 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- APEBUJBRGCMMHP-HJWJTTGWSA-N Val-Ile-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 APEBUJBRGCMMHP-HJWJTTGWSA-N 0.000 description 1
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 102220369446 c.1274G>A Human genes 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001178—Tumor rejection antigen precursor [TRAP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
公开了具有增强的免疫原性的组合物。该组合物含有一种或多种肽类,当这些肽类与一种细胞表面分子如MHC,HLA或B细胞受体结合时,能够引起免疫应答。该组合物含有加强免疫应答的佐剂如皂苷。尤其优选的组合物是能够刺激胞溶性T细胞应答的组合物,如那些能够满足MHC结合标准的肽类,例如衍生于肿瘤排斥抗原前体的肽类,包括MAGE,BAGE以及GAGE衍生肽类。
Description
相关申请
本申请是以下所有申请的部分继续申请,这些申请讨论了在复合的肿瘤排斥抗原和MHC/HLA分子的存在下对胞溶性T细胞的激发:PCT申请PCT/US92/04354(指定美国);申请号938,334,申请日1992年8月31日;申请号008,446,申请日1993年1月22日;申请号54,714,申请日1993年4月28日;申请号203,054,申请日1994年2月28日;申请号233,305,申请日1994年4月26日;申请号195,186,申请日1994年2月14日;申请号196,630,申请日1994年2月15日;申请号32,978,申请日1993年3月18日;申请号217,186;217,187和217,188,申请日均为1994年3月24日;申请号190,411,申请日1994年4月1日以及申请号253,503,申请日1994年6月3日。
发明领域
本发明涉及用于产生针对肿瘤排斥抗原前体(“TRAPs”)和肿瘤排斥抗原(“TRAs”)分子的免疫应答的组合物。其免疫应答包括,抗TRAPs和TRAs的抗体的产生,以及对TRA与主要组织相容性分子的复合物具有特异性的T细胞的产生。这些T细胞和抗体能够在小鼠,大鼠,兔,绵羊,山羊和其它非人类动物中产生,然后用于诊断肿瘤的存在。通过将其给予具有癌变症状的对象或细胞转化已经发生的个体,该组合物还可用于治疗以引起针对肿瘤、癌细胞和转化细胞的免疫应答。这些癌变包括黑素瘤或发育异常的痣。
背景和现有技术
针对宿主生物对肿瘤细胞的识别或这种识别作用的缺失的研究已在许多不同的分支方向上进行。对该领域的了解意味着对基础免疫学和肿瘤学的一些了解。
早期对小鼠肿瘤的研究揭示了当将小鼠肿瘤移植到同源动物中会显现导致肿瘤细胞排斥反应的分子。这些分子在受体动物中被T细胞“识别”,并唤起胞溶性T细胞的反应,溶解移植的细胞。这种现象首先在体外通过化学致癌物,如甲基胆蒽诱发的肿瘤中发现。还发现在每种肿瘤中,肿瘤表达的抗原及其引发的T细胞反应是不同的。见Prehn,et al.,J.Natl.Canc.Inst.18:769-778(1957);Klein,et al.,Cancer Res.3:326-333(1943);Basombrio,Cancer Res.30:2458-2462(1970),这些文献教导了用化学致癌物对肿瘤的诱导以及细胞表面抗原的不同。这种抗原被称作肿瘤特异性移植抗原或“TSTAs”。在观察到此类由化学诱变剂引起的抗原之后,类似的结果在体外用紫外线照射产生的肿瘤中也有发现。见Kripke,J.Natl.Canc.Ins.53:333-1336(1974)。
尽管在如上所述的肿瘤中观察到T细胞介导的免疫应答,但自发性肿瘤一般被认为是非免疫原性的。因此据信在带有肿瘤的对象中不存在可引起免疫应答的抗原。见Hewitt,et al.,Brit.J.Cancer,33:241-259(1976)。
呈递tum-抗原家族的细胞株是通过诱变小鼠肿瘤细胞或细胞株得到的免疫原性变异体。见Boon et al.,J.Exp.Med.152:1184-1193(1980),该文献引入本文作参考。详细地说,tum-抗原是通过突变在同源小鼠中不产生免疫应答并形成肿瘤的肿瘤细胞(即tum+细胞)而得到的。当这些tum+细胞被诱变时,它们在同源小鼠中被排斥,不能形成肿瘤(tum-),见Boon et al.,Proc.Natl.Acad.Sci.USA 74:272(1977),该文献引入本文作参考。许多肿瘤类型都显示出这一现象。见Frost et al.,Cancer Res.43:125(1983)。
tum-变异体似乎不能形成肿瘤,因为它们能引起免疫排斥过程。证实这个假说的证据包括:不能正常形成肿瘤的tum-变异体在那些免疫系统被亚致死剂量的射线破坏的小鼠中又恢复了形成肿瘤的能力。见Van Pel et al.,Proc.Natl.Acad.Sci.USA 76:5282-5285(1979)。而且,外周注射的肥大细胞瘤细胞株P815的tum-细胞指数增长12-15天,然后这些细胞在给予巨噬细胞和淋巴细胞几天后就消失了(Uyttenheve et al.,J.Exp.Med.152:1175-1183(1980))。类似的证据还包括,观察到获得免疫记忆的小鼠,其在通过射线处理破坏免疫系统后,在相同的tum-变异体的攻击中能够存活下来。(Boon et al.,Proc.Natl.Acad.Sci.USA 74:272-275(1977);Van Pel et al.,同上;Uyttenheve et al.,同上)。后来的研究发现,当诱变自发性肿瘤时,能产生能引起免疫应答的免疫原性变异体。事实上,这些变异体能够产生针对原始肿瘤的免疫保护性反应。见Van Pel et al.,J.Exp.Med.157:1192-2001(1983)。因此,已经发现在一个是同源排斥反应靶的肿瘤中产生一种叫做“肿瘤排斥抗原”的呈递是可能的。类似的结果在外源基因导入自发性肿瘤时也已得到。见Fearson et al.,Cancer Res.48:2975-1980(1988)。
已识别出一类抗原,它存在于肿瘤细胞表面,并能够被胞溶性T细胞所识别,导致细胞溶解。这类抗原在此后将被称作“肿瘤排斥抗原”或“TRAs”。TRAs可能会也可能不会引起抗体反应。已通过对胞溶性T细胞的体外鉴定研究,即通过特定的胞溶性T细胞(以下称“CTL”)对抗原的鉴定研究,对这些抗原进行了研究。CTL通过识别呈递的肿瘤排斥抗原而增殖,从而呈递这些抗原的细胞被溶解。鉴定研究已经鉴定出能够特异性溶解表达这类抗原的细胞的CTL克隆。这类工作的例子可见以下的文献:Levy etal.,Adv.Cancer Res.24:1-59(1977);Boon et al.,J.Exp.Med.152:1184-1193(1980);Brunner et al.,J.Immunol.124:1627-1634(1980);Maryanski et al..Eur.J.Immunol.124:1627-1634(1980);Maryanski et al.,Eur.J.Immunol.32:406-412,(1982);Palladino etal.,Canc.Res.47:5074-5079(1 987)。被CTL识别的其它种类的抗原也要求进行这类分析,其它抗原种类包括主要组织相容性抗原,雄性特异性H-Y抗原,以及一类在此讨论的称作“tum-”抗原的抗原。
一种如上所述的肿瘤的例子是P815。见DePlaen et al.,Proc.Natl.Acad.Sci.USA 85:2274-2278(1988);Szikora et al.,EMBO J.9:1041-1050(1990);Sibille et al.,J.Exp.Med.172:35-45(1990),这些文献引入本文作参考。P815肿瘤是一种肥大细胞瘤,用甲基胆蒽诱变于DBA/2小鼠,可以作为体外肿瘤或细胞株培养。P815细胞株诱变后产生许多tum-变异体,包括P91A变异体(DePlaen,同上);35B(Szikora,同上);以及P198(Sibille,同上)。与肿瘤排斥抗原相反----这是一个关键----tum-抗原仅仅在诱变之后呈递。肿瘤排斥抗原存在于没有诱变的给定肿瘤的细胞中。因此,如参考文献中所述,一个细胞株可能是tum+的,例如“P1”细胞株,也能被诱发产生tum-变异体。既然tum-表型与其亲本细胞株不同,可以预料,tum-细胞株的DNA与其亲本tum+细胞株相比也有区别,而且这种区别可以被开发用来定位tum-细胞中的感兴趣的基因。结果,发现tum-变异体如P91A,35B和P198的基因与其正常等位基因不同,在基因的编码区发生了点突变。见Szikora and Sibille,同上;以及Lurquin et al.,Cell 58:293-303(1989)。已证明本发明的TRAs不属于这种情况。这些文献也说明了源于tum-抗原的肽类被Ld分子所呈递,以便被CTLs所识别,P91A被Ld,P35B被Dd,P198被Kd所呈递。
以前的专利申请PCT/US92/04 354,US申请号807,043;764,364;728,838和705,702(所有均引为参考文献)以及U.S.专利5,342,774,描述了有关编码各种TRAPs(其依次被加工成肿瘤排斥抗原,或称“TRAs”)的基因或其它核酸分子的发明。作为本申请的一部分的SEQ ID NOs:1-26列出了编码各种TRAPs以及以下称为MZ2E(它源于MAGE-1 TRAP(SEQ ID NO:26))的基因序列。
这些基因可以用来产生分离的和纯化的肿瘤排斥抗原前体和TRA本身,它们都可以作为治疗癌症的药物,其中,抗原可作为“标记物”。它们还可以用于各种肿瘤学诊断或延缓肿瘤病人病情的治疗中,以下将讨论之。已知例如,tum-细胞可以用来产生可溶解呈递不同的tum-抗原的细胞和tum+细胞的CTLs。见Maryanski,et al.,Eur.J.Immunol.12:401(1982);Van Der Eynde et al.,Modern Trends in Leukemia IX(June,1990),这些文献引入本文作参考。肿瘤排斥抗原前体可以通过转染了基因的细胞表达,然后用来产生针对感兴趣的肿瘤的免疫应答。
与类似的人类肿瘤形成中,已观察到自体混合的淋巴细胞肿瘤细胞培养物(“MLTC”)经常能够产生可溶解自体肿瘤细胞而不溶解其天然杀伤靶、自体EBV-转化B细胞或自体成纤维细胞的效应淋巴细胞(见Anichini et al.,Immunol.Today8:385-389,(1987))。这种应答在黑素瘤中研究的较多,而且,MLTC被外周血细胞或肿瘤浸润淋巴细胞携带。这类文献的例子有Knuth et al.,Proc.Natl.Acad.Sci.USA86:2804-2802(1984);Mukherji et al.,J.Exp.Med.158:240(1983);Herinet al.,Int.J.Canc.39:390-396(1987);Topalian et al.,J.Clin.Oncol.6:839-853(1988)。稳定的胞溶性T细胞克隆衍生于MLTC效应细胞,而且这些克隆是肿瘤细胞特异性的。见Mukherji et al.,同上;Herin et al.,同上;Knuth et al.,同上。通过这些自体CTLs细胞在肿瘤细胞中识别的抗原不会代表人工培养假象,因为它们在体内的肿瘤细胞中也被发现。Topalian et al.,同上;Degiovanni et al.,Eur.J.Immunol.20:1865-1868(1990)。这些观察到的现象,再结合用于本文的分离特异性小鼠肿瘤排斥抗原前体基因的技术,就可用来分离编码在人肿瘤上呈递的TRAs的肿瘤排斥抗原前体的核酸。现在已经能够分离编码肿瘤排斥抗原前体的核酸序列。这些肿瘤排斥抗原前体包括但不限于特定肿瘤的最具特征的那些。其应用将在以下描述。
另外的工作集中在TRAs被所称的主要组织相容性复合物(“MHCs”)呈递方面。这些分子的人源形式是“人类白细胞抗原”或称“HLAs”。这项工作得到了一些意想不到的结果。特别在U.S.专利申请号938,334,即现在的美国专利______中(该文献引入本文作参考),教导了一种被HLA-A1分子呈递的九肽。文献中说,已知一种对特定HLA分子具有特异性的特定肽,应该能够预期到特定的结合一种HLA分子的肽。这类肽,本文是SEQ ID NO:27-34也由Traversari et al.,J.Exp.Med.176:1453-1457(1992)描述。这一点是极其重要的,因为不同的个体具有不同的HLA表型。其结果是,尽管鉴定出特定的肽或特定的基序以及含有该肽或基序作为其一部分的肽是特异HLA分子的配体具有诊断和治疗作用,但它们仅仅与具有该特定的HLA分子表型的个体相关。因此,在该领域需要进行更多的工作,因为细胞异常现象并非仅局限于某一种特定的HLA分子表型,而且,定向疗法要求对异常细胞的表型有一些了解。
U.S.专利申请号008,446(申请日1993年1月22日,引入本文作参考),揭示了MAGE-1表达产物被加工成第二种TRA这一事实。该第二种TRA被HLA-Cw*1601分子呈递。该发现说明一种给定的TRAP能够产生多种TRAs。
U.S.专利申请号994,928(申请日1992年12月22日,引入本文作参考),描述了作为肿瘤排斥抗原前体的酪氨酸酶。这是一个熟知的分子,如见Kwon,U.S.专利4,898,814。该文献揭示,某些正常细胞(如黑素细胞)产生的一种分子,也能在肿瘤细胞中被加工成能够被HLA-A2分子呈递的肿瘤排斥抗原。由其呈递的肽在U.S.专利申请号54,714,(申请日1993年4月28日)中有描述。SEQ ID NO:35示出该肽。另外的被HLA-A2分子呈递的酪氨酸酶衍生肽见U.S.专利申请号203,054和233,305,(申请日分别为1994年2月28日和1994年4月26日,引入本文作参考)(SEQ ID NO:36-41)。
其它的一些TRAs肽类描述于另外的专利申请中。U.S.专利申请号195,186(申请日1994年2月14日,引入本文作参考)提出了三种肽(SEQ ID NO:42-44),它们衍生于MAGE-1且与HLA-Cw*1601复合。U.S.专利申请号196,630(申请日1994年2月15日,引入本文作参考)揭示了一种不相关的肿瘤排斥抗原前体,叫做“BAGE”基因,以及衍生的肽类,它能被加工然后被HLA-Cw*1601呈递,见SEQ ID NO:45-48。SEQ ID NO:48是肿瘤排斥抗原。另外的编码肿瘤排斥抗原前体的序列见申请号32,978(申请日1993年3月18日,引入本文作参考),这些序列见本文的SEQ ID NOS:49和50。此基因的一个更长的序列描述于申请号272,351(申请日1994年7月8日,引入本文作参考),它是SEQ ID NO:51。在申请号96,039(申请日1993年7月22日)中,有肿瘤排斥抗原前体GAGE的序列,见SEQ ID NO:52。
一系列的当被MHC分子呈递时能够唤起胞溶性T细胞的溶解反应的肽可见申请号217,186,申请号08/217,188,申请号217,187(申请日均为1994年3月24日,均引入本文作参考)。这三个申请中的第一个揭示了被HLA-A2呈递的MAGE-3衍生肽。感兴趣的有5种肽,即SEQ ID NO:53-57。第二个申请报导了11种衍生于MAGE-2的序列,据信它们能够与HLA-A2分子复合(SEQ ID NO:58-68)。最后一个申请中揭示了两种另外的肽(SEQ ID NO:69,70),它们源于MAGE-3,并于HLA-A2复合。申请号190,411(申请日1994年4月1日,引入本文作参考)揭示了三种肽(SEQ ID NO:71-73)。它们衍生于MAGE-1,它们是免疫原性的因为在给予它们的宿主动物中可引起抗体的产生。申请号253,503(申请日1994年6月3日,引入本文作参考)提出了另一种肿瘤排斥抗原前体基因(SEQ ID NO:74),以及一种衍生于它的肽,SEQ ID NO:75,它被HLA-B44呈递。另外,在Coulie,Ikeda和Boon-Falleur等人同时递交的专利申请中,提出了一种编码已知为DAGE的肿瘤排斥抗原前体的序列(SEQ ID NO:76)。DAGE在肿瘤细胞中极其普遍,而在正常细胞中的表达仅见于睾丸细胞。这就使得它在癌症诊断以及本文所述的其它应用中特别有用。上述名单并非有关TRAPs或TRAs的文献的全部罗列,而是表示其多样性,以及这样一种事实:这些物质不仅仅能够唤醒T细胞的增殖,而且可刺激抗体的产生。已知产生抗体的细胞可用来生产杂交瘤细胞,而杂交瘤细胞能生产单克隆抗体。因此,当“抗体”这个词用于本文时,它包括多克隆抗体和单克隆抗体。
本发明的母申请,包括申请号142,368和190,411,都讨论了TRAPs或TRAs与各种物质如佐剂联合时的用途,如生产疫苗,免疫原性组合物,等等。佐剂,广义说来,是促进免疫应答的物质。通常地,选择的佐剂是弗氏完全佐剂,或失活的B.pertussis生物体,可用于与氢氧化铝吸附的抗原结合。有关佐剂的一般性论述可见Goding,单克隆抗体:理论与实践(第二版,1986),第61-63页,引入本文作参考。Goding提出,当所感兴趣的抗原分子量较低,或是免疫原性较差时,可以偶联上一种免疫原性载体。根据Goding所说,这些分子的分子量一般低于1,000。在Goding所建议的载体中,有匙孔戚血蓝蛋白,牛血清白蛋白,卵白蛋白,以及禽类免疫球蛋白。
有关这些载体的选择的难点,在于它们本身是具有免疫原性的。因此,免疫应答可能是一个总的反应,其中一部分,大部分甚至全部是针对载体分子而不是免疫原分子本身。
现有技术中有关佐剂的发展的例子可见U.S.专利5,057,540(Kensil et al.,引入本文作参考)。Kensil等人揭示了各种皂苷提取物制备物,它们可用作免疫原性组合物的佐剂。作为天然产物,提取物的成分并未完全得到确定。Kensil等人提供了一份完整的有关不同提取物包括QA-7,QA-19和QA-21(也称作QS-21)的制备方法。在进行的实验中,牛血清白蛋白(“BSA”)与不同的提取物(实施例8和9)结合,测试了吸附到氢氧化铝上的猫科动物白血病病毒重组糖蛋白“gp70RΔ”。当然,所试验的这两种免疫原,预期它们都有自身的免疫原性(gp70RΔ的分子量为70kd,BSA的分子量类似)。对那些被认为免疫原性很差甚至没有的分子没有进行试验,因此可以预计它们要使用氢氧化铝吸附或使用半抗原性载体以激发应答。
在PCT申请WO9219758(其相应于防御性公开7697275,引入本文作参考)中,揭示了一种称为“MTP-MF59”的佐剂。该佐剂用于与Plasmodium falciparun蛋白“Pfs-25-B”连接。这种结合被描述为传递阻断疫苗(transmission blocking vaccine)。P.falciparum蛋白本身已大得足够产生免疫原性。因此,在现有技术中没有说明该改进后的佐剂可以用于与推断为非免疫原性蛋白质或肽结合而得到免疫学有效的组合物。对于在上面所引的文献中的TRAPs和TRAs分子,尤其是如此。
现在令人吃惊地发现,可以制备当对动物给药时能够产生免疫应答的包括肿瘤排斥抗原前体或肿瘤排斥抗原的组合物。在特别优选的实施方案中,组合物的免疫原性部分由一种或多种TRAP或更优选是TRA分子,以及佐剂组成。特别优选的组合物中,佐剂是如上述引为参考文献的Kensil等人的专利所公开的QS21。
本发明中的免疫原由TRAPs或TRAs组成,即意味着不包括半抗原,载体,沉淀氢氧化铝,或其它一些通常用来与免疫原性很差或被认为免疫原性很差的分子结合的物质。在特别优选的实施方案中,组合物基本上由免疫原和佐剂组成。
在下面详细地对本发明进行描述。
优选实施方案的详细描述
实施例
下面的实施例阐述了与佐剂QS-21联合使用时,肽MZ2E(SEQ ID NO:26)的用法。应该明白的是,其中的蛋白质或肽(组合物的第一个成分)和佐剂(组合物的第二个成分)是可以替换的。MZ2E和QS21的结合的未预料的效果应在其他结合即使用其它肽时也应发生。
试验的对象是处于IV期黑素瘤或高危性III期恶性黑素瘤患者。IV期患者在确诊以后平均有一年的存活期,只有15%的长期生存机会(Balch,et al.,Cutaneous Melanoma,J.B.Lippincott,Philadelphia,1992)。对这类患者的标准疗法包括用去卡巴肼(decarbazine)或与去卡巴肼联合的药物治疗,然而,有效率仅有8-25%,而且没有证据能够说明治疗可以延长生命,见Balch et al.,同上。高危性III期黑素瘤患者(PT4厚躯干初期肿瘤或大范围的黑素瘤,有5个或更多个阳性区域淋巴结)的平均存活期为1-2年,长期生存机会仅有19%,见Balch et al.,同上。
研究中所用的12位患者,都是依据上述标准用组织学方法确定的IV期或高危性III期黑素瘤患者。
患者还满足以下附加的标准:
(i)手术后已完全康复;
(ii)在免疫接种之前的四周内未接受过化学治疗或免疫治疗;
(iii)预期至少尚有三个月的存活期;
(iv)Karnofski Performance Status为60或更多;
(v)有如下的化验结果:
粒细胞 ≥2,500/min3
淋巴细胞 ≥700/min3
血小板 ≥100,000/min3
血清肌红蛋白≤2.0mg/100ml
血清胆红素 ≤2.0mg/100ml
(vi)对于MZ2E接种,患者是HLA-A2阳性;
(vii)对于MZ2E接种,患者肿瘤表达MAGE-1;
(viii)年龄超过19周岁,且有书写填表能力。
凡符合以下标准之一的任何潜在对象均被排除:
(i)临床上明显的心脏病;
(ii)其它严重疾病,例如需要使用抗生素治疗的感染,或出血异常;
(iii)正在使用抗组氨酸,N-SAIDS,或固醇类药物治疗;
(iv)有免疫缺陷,脾切除,或对脾进行了放射疗法;
(v)处于孕期或哺乳期;
(vi)未使用有效避孕方法的育龄期妇女。
所有对象均作为门诊病人处理。使用溶于0.3ml的pH7.4的磷酸缓冲液的MZ2E(30微克或300微克)和QS21(100微克)对其进行皮下接种。其中6位患者用30微克肽,另6位用300微克。首次注射在腿内侧的三角区,随后依次变化注射位点。未在流脓的淋巴结已经手术切除或放疗过的肢体上注射。
注射首次在第1天,然后依次在第8,15,22和57天进行。患者要被监测12周,除非有必要中断(由调查者确定)。那些表现出稳定性的或是有肿瘤反应的患者保留在研究中,直到病情的发展被确定之后。如果观察到毒性反应,患者也可以离开本项研究或接受不同剂量的肽。
患者表现出如下的反应。在一种完全反应中,肿瘤的所有症候、症状、生物化学和图象证据都在至少30天之内消失。在一种部分反应中,在至少30天之内所有可测肿瘤的尺寸较最大直径和垂直直径总和至少有50%的减少,而且没有新的损害出现或是任何新的损害的发展。在一种较小的反应中,在至少30天之内所有可测肿瘤的尺寸较最大直径和垂直直径总和至少有25%的减少,而且没有新的损害出现或是损害的发展。在病情稳定的反应中,在至少30天之内尺寸变化低于最大直径和垂直直径总和的25%,而且没有新的损害出现或是损害的发展。在病情有发展的反应中,有新的肿瘤出现,或是可测肿瘤的尺寸较最大直径和垂直直径总和至少有50%的增加。
上述实施例阐述了一种包括一定量的肿瘤排斥抗原,即MZ2E,和一种佐剂,即QS21的组合物,以及该组合物在体内治疗癌症(例如黑素瘤)的应用。所用的肿瘤排斥抗原的量要足以引起针对其表面呈递这些抗原的肿瘤细胞的免疫应答。
本发明的组合物包括与一种药学上可接受的佐剂联合应用的任何肿瘤排斥抗原前体(“TRAP”)或肿瘤排斥抗原(“TRA”)。本发明的优选实施方案使用的是上述讨论过的与SEQ ID NO:65相应的TRAPs和TRAs,以及在背景部分描述过的佐剂。
从上述讨论可见,本发明的一个重要方面是刺激T细胞的增殖。它可能是一种初始的刺激作用,或是对已有的刺激的增强作用。特别地,希望的是刺激在其表面呈递如上所述的TRAs之类的肽的胞溶性T细胞。胞溶性T细胞识别这些MHC与肽的复合物,通过它们的受体与之结合,并且增殖。它们还溶解所识别的细胞。这种应答不仅在体内,而且在体外也可应用,因为已熟知特定的MHC和肽的复合物有特异性的CTLs细胞存在于经历了细胞转化的对象的血液中。通过使个体的血样在体外与感兴趣的肽以及呈递感兴趣的MHC分子的细胞接触,在血样中的胞溶性T细胞就会扩增,即增殖。这种增殖作用可以通过任何已知的分析方法测得。特别优选的是放射性铬(51Cr)释放分析,以及测定肿瘤坏死因子(TNF)的释放。
该组合物还可用作B细胞增殖或抗体产生的刺激物。众所周知的是,B细胞产生抗体,而且它们的靶的大小正好在肿瘤排斥抗原,当然也在肿瘤排斥抗原前体的大小范围之内。与T细胞的情形一样,这种刺激作用可以在体内或是在体外,可能是“初始的”,或是已有反应的增强。
所用的TRAP或TRA的量将根据免疫接种的目的和给药对象而有所变化。例如,在产生用于如诊断呈递TRA的癌细胞的存在的小鼠抗体时,所用的蛋白质或肽的量可以比用在诸如上述实施例中描述的体内治疗过程中的量要少。一般地,优选的剂量是每剂从大约1微克到大约750微克蛋白质或肽。在一个优选的实施方案中,范围是从约10微克到约500微克。最优选的是,每剂使用大约30微克到大约300微克。当然,在本发明的治疗应用中,调查者可以调整剂量,因为一个6个月的婴儿和一个成年人所需的剂量肯定有所不同。给药的方式可以变化,优选的方式是口服,皮下,肌肉,静脉或腹膜内给予。
在组合物中的TRAP或TRA的选择将依赖于技术人员可确定的参数。这是熟知的技术,例如,不同的TRAs被不同的MHC分子呈递。例如,一旦通过已知的技术将一个对象鉴定为其肿瘤细胞表面呈递HLA-A2分子之后,将会使用被HLA-A2呈递的TRA而不会选择被例如HLA-Cw*1601所呈递的。同样地,使用例如聚合酶链式反应(PCR),溶解研究,以及其它一些技术上已知的分析方法,可以确定对象患者所表达的是哪种或哪几种肿瘤排斥抗原前体基因,由此将决定使用什么蛋白质或肽。再者,例如说,如果一个对象的肿瘤细胞表达的是MAGE-3而不是MAGE-1,则所选择的免疫接种的肽应该是衍生于MAGE-3的而不是MAGE-1的。
尽管本文所讨论的分子被称为“肿瘤”排斥抗原和“肿瘤”排斥抗原前体,但应理解的是它们在治疗和诊断上的应用可以超出癌症的范围。现有技术熟知,一些病理学状态例如发育异常的痣,其不是癌症,但患病个体的细胞确以转化为特征。任何和所有如此的状态均在本发明的范围内。
本发明的其它方面对于熟练技术人员来说是很清楚的,在此不再赘述。
所用的术语或表达方式是用作描述而非限定的,没有使用这些术语或表达方式来排除任何等价的所显示和描述的特性的意图,应该明白的是,在本发明的范围之内,各种改变将是可能的。(1)一般信息:(i)申请人:蒂尔瑞·博恩-法勒尔;贝努瓦·范登艾恩德;
皮埃尔·范德布鲁根(ii)发明名称:含有肿瘤排斥抗原前体或肿瘤排斥抗原以及佐剂和/或生长
因子的组合物(iii)序列数:76(iv)通讯信息:
(A)收信人:Felfe&Lynch
(B)街道:805 Third Avenue
(C)城市:纽约市
(D)州:纽约州
(E)国家:美国
(F)邮码:10022(v)计算机可读形式:
(A)媒介类型:软盘,5.25英寸,360kb存贮量
(B)计算机:IBM PS/2
(C)操作系统:PC-DOS
(D)软件:Wordperfect(vi)目前申请资料:
(A)申请号:08/315,961
(B)申请日:1994年9月30日
(C)分类:435(vii)在先申请资料:
(A)申请号:PCT/US92/04354
(B)申请日:1992年5月22日(vii)在先申请资料:
(A)申请号:07/938,334
(B)申请日:1992年8月31日(vii)在先申请资料:
(A)申请号:08/008,446
(B)申请日:1993年1月22日 (vii)在先申请资料:
(A)申请号:08/054,714
(B)申请日:1993年4月28日(vii)在先申请资料:
(A)申请号:08/203,054
(B)申请日:1994年2月28日(vii)在先申请资料:
(A)申请号:08/233,305
(B)申请日:1994年4月26日(vii)在先申请资料:
(A)申请号:08/195,186
(B)申请日:1994年2月14日(vii)在先申请资料:
(A)申请号:08/196,630
(B)申请日:1994年2月15日(vii)在先申请资料:
(A)申请号:08/032,978
(B)申请日:1993年3月18日(vii)在先申请资料:
(A)申请号:08/217,186
(B)申请日:1994年3月24日(vii)在先申请资料:
(A)申请号:08/217,187
(B)申请日:1994年3月24日(vii)在先申请资料:
(A)申请号:08/217,188
(B)申请日:1994年3月24日(vii)在先申请资料:
(A)申请号:08/190,411
(B)申请日:1994年4月1日(vii)在先申请资料:
(A)申请号:08/253,503
(B)申请日:1994年6月3日(viii)律师/代理人信息:
(A)姓名:Hanson,Norman D.
(B)注册号:30,946
(C)案号/文档号:LUD 5370(ix)电讯信息:
(A)电话:(212)688-9200
(B)传真:(212)838-3884(2)SEQ ID NO.1的信息(i)序列特征:
(A)长度:462bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(xi)序列描述:SEQ ID NO.1ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT GAAGATCCTG 60ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT CAGCCAATGA GCTTACTGTT 120CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG 180CTTGTGAATT TGTACCCTTT CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC 240CCCCCTCCCA CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG CATGCATTGT 360GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG CTAGCTTGCG ACTCTACTCT 420TATCTTAACT TAGCTCGGCT TCCTGCTGGT ACCCTTTGTG CC 462(2)SEQ ID NO.2的信息(i)序列特征:
(A)长度:675bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(xi)序列描述:SEQ ID NO.2ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA GGT GGT 48Met Ser Asp Asn Lys Lys Pro Asp Lys Ala His Ser Gly Ser Gly Gly
5 10 15GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG TAC TCC CTG GAA 96Asp Gly Asp Gly Asn Arg Cys Asn Leu Leu His Arg Tyr Ser Leu Glu
20 25 30GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC TTC GCT GTT GTC ACA ACA 144Glu Ile Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Val Val Thr Thr
35 40 45AGT TTT CTG GCG CTC CAG ATG TTC ATA GAC GCC CTT TAT GAG GAG CAG 192Ser Phe Leu Ala Leu Gln Met Phe Ile Asp Ala Leu Tyr Glu Glu Gln
50 55 60TAT GAA AGG GAT GTG GCC TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC 240Tyr Glu Arg Asp Val Ala Trp Ile Ala Arg Gln Ser Lys Arg Met Ser65 70 75 80TCT GTC GAT GAG GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC 288Ser Val Asp Glu Asp Glu Asp Asp Glu Asp Asp Glu Asp Asp Tyr Tyr
85 90 95GAC GAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 336Asp Asp Glu Asp Asp Asp Asp Asp Ala Phe Tyr Asp Asp Glu Asp Asp
100 105 110GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA GAT GAG 384Glu Glu Glu Glu Leu Glu Asn Leu Met Asp Asp Glu Ser Glu Asp Glu
115 120 125GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA GCT GAG GAA ATG 432Ala Glu Glu Glu Met Ser Val Glu Met Gly Ala Gly Ala Glu Glu Met
130 135 140GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT GGC CAT CAT TTA AGG AAG 480Gly Ala Gly Ala Asn Cys Ala Cys Val Pro Gly His His Leu Arg Lys145 150 155 160AAT GAA GTG AAG TGT AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC 528Asn Glu Val Lys Cys Arg Met Ile Tyr Phe Phe His Asp Pro Asn Phe
165 170 175CTG GTG TCT ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT 576Leu Val Ser Ile Pro Val Asn Pro Lys Glu Gln Met Glu Cys Arg Cys
180 185 190GAA AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG 624Glu Asn Ala Asp Glu Glu Val Ala Met Glu Glu Glu Glu Glu Glu Glu
195 200 210GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT 672Glu Glu Glu Glu Glu Glu Glu Met Gly Asn Pro Asp Gly Phe Ser Pro220 225 230 235TAG 675(2)SEQ ID NO.3的信息(i)序列特征:
(A)长度:228bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(xi)序列描述:SEQ ID NO.3GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG TTGTTTTTTT 60TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA ATTTGATTTT GTTCTAAAGT 120TCATTATGCA AAGATGTCAC CAACAGACTT CTGACTGCAT GGTGAACTTT CATATGATAC 180ATAGGATTAC ACTTGTACCT GTTAAAAATA AAAGTTTGAC TTGCATAC 228(2)SEQ ID NO.4的信息(i)序列特征:
(A)长度: 1365bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(xi)序列描述:SEQ ID NO.4ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG 150AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT 200CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG 350CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450ACCCTTTGTG CC 462ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA 504GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG 546TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC 588TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC 630ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC 672TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG 714GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC 756GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 798GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA 840GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA 882GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT 924GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT AGG ATG ATT 966TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT ATA CCA GTG 1008AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA AAT GCT GAT 1050GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG GAG GAG 1092GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT 1134TAG 1137GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG 1187TTGTTTTTTT TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA 1237ATTTGATTTT GTTCTAAAGT TCATTATGCA AAGATGTCAC CAACAGACTT 1287CTGACTGCAT GGTGAACTTT CATATGATAC ATAGGATTAC ACTTGTACCT 1337GTTAAAAATA AAAGTTTGAC TTGCATAC 1365(2)SEQ ID NO.5的信息(i)序列特征:
(A)长度:4698bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(xi)序列描述: SEQ ID NO.5ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG 150AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT 200CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG 350CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450ACCCTTTGTG CC 462ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA 504GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG 546TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC 588TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC 630ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC 672TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG 714GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC 756GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 798GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA 840GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA 882GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC T 916GTGAGTAACC CGTGGTCTTT ACTCTAGATT CAGGTGGGGT GCATTCTTTA 966CTCTTGCCCA CATCTGTAGT AAAGACCACA TTTTGGTTGG GGGTCATTGC 1016TGGAGCCATT CCTGGCTCTC CTGTCCACGC CTATCCCCGC TCCTCCCATC 1066CCCCACTCCT TGCTCCGCTC TCTTTCCTTT TCCCACCTTG CCTCTGGAGC 1116TTCAGTCCAT CCTGCTCTGC TCCCTTTCCC CTTTGCTCTC CTTGCTCCCC 1166TCCCCCTCGG CTCAACTTTT CGTGCCTTCT GCTCTCTGAT CCCCACCCTC 1216TTCAGGCTTC CCCATTTGCT CCTCTCCCGA AACCCTCCCC TTCCTGTTCC 1266CCTTTTCGCG CCTTTTCTTT CCTGCTCCCC TCCCCCTCCC TATTTACCTT 1316TCACCAGCTT TGCTCTCCCT GCTCCCCTCC CCCTTTTGCA CCTTTTCTTT 1366TCCTGCTCCC CTCCCCCTCC CCTCCCTGTT TACCCTTCAC CGCTTTTCCT 1416CTACCTGCTT CCCTCCCCCT TGCTGCTCCC TCCCTATTTG CATTTTCGGG 1466TGCTCCTCCC TCCCCCTCCC CCTCCCTCCC TATTTGCATT TTCGGGTGCT 1516CCTCCCTCCC CCTCCCCAGG CCTTTTTTTT TTTTTTTTTT TTTTTTTTTT 1566TTGGTTTTTC GAGACAGGGT TTCTCTTTGT ATCCCTGGCT GTCCTGGCAC 1616TCACTCTGTA GACCAGGCTG GCCTCAAACT CAGAAATCTG CCTGCCTCTG 1666CCTCCCAAAT GCTGGGATTA AAGGCTTGCA CCAGGACTGC CCCAGTGCAG 1716GCCTTTCTTT TTTCTCCTCT CTGGTCTCCC TAATCCCTTT TCTGCATGTT 1766AACTCCCCTT TTGGCACCTT TCCTTTACAG GACCCCCTCC CCCTCCCTGT 1816TTCCCTTCCG GCACCCTTCC TAGCCCTGCT CTGTTCCCTC TCCCTGCTCC 1866CCTCCCCCTC TTTGCTCGAC TTTTAGCAGC CTTACCTCTC CCTGCTTTCT 1916GCCCCGTTCC CCTTTTTTGT GCCTTTCCTC CTGGCTCCCC TCCACCTTCC 1966AGCTCACCTT TTTGTTTGTT TGGTTGTTTG GTTGTTTGGT TTGCTTTTTT 2016TTTTTTTTTT GCACCTTGTT TTCCAAGATC CCCCTCCCCC TCCGGCTTCC 2066CCTCTGTGTG CCTTTCCTGT TCCCTCCCCC TCGCTGGCTC CCCCTCCCTT 2116TCTGCCTTTC CTGTCCCTGC TCCCTTCTCT GCTAACCTTT TAATGCCTTT 2166CTTTTCTAGA CTCCCCCCTC CAGGCTTGCT GTTTGCTTCT GTGCACTTTT 2216CCTGACCCTG CTCCCCTTCC CCTCCCAGCT CCCCCCTCTT TTCCCACCTC 2266CCTTTCTCCA GCCTGTCACC CCTCCTTCTC TCCTCTCTGT TTCTCCCACT 2316TCCTGCTTCC TTTACCCCTT CCCTCTCCCT ACTCTCCTCC CTGCCTGCTG 2366GACTTCCTCT CCAGCCGCCC AGTTCCCTGC AGTCCTGGAG TCTTTCCTGC 2416CTCTCTGTCC ATCACTTCCC CCTAGTTTCA CTTCCCTTTC ACTCTCCCCT 2466ATGTGTCTCT CTTCCTATCT ATCCCTTCCT TTCTGTCCCC TCTCCTCTGT 2516CCATCACCTC TCTCCTCCCT TCCCTTTCCT CTCTCTTCCA TTTTCTTCCA 2566CCTGCTTCTT TACCCTGCCT CTCCCATTGC CCTCTTACCT TTATGCCCAT 2616TCCATGTCCC CTCTCAATTC CCTGTCCCAT TGTGCTCCCT CACATCTTCC 2666ATTTCCCTCT TTCTCCCTTA GCCTCTTCTT CCTCTTCTCT TGTATCTCCC 2716TTCCCTTTGC TTCTCCCTCC TCCTTTCCCC TTCCCCTATG CCCTCTACTC 2766TACTTGATCT TCTCTCCTCT CCACATACCC TTTTTCCTTT CCACCCTGCC 2816CTTTGTCCCC AGACCCTACA GTATCCTGTG CACAGGAAGT GGGAGGTGCC 2866ATCAACAACA AGGAGGCAAG AAACAGAGCA AAATCCCAAA ATCAGCAGGA 2916AAGGCTGGAT GAAAATAAGG CCAGGTTCTG AGGACAGCTG GAATCTAGCC 2966AAGTGGCTCC TATAACCCTA AGTACCAAGG GAGAAAGTGA TGGTGAAGTT 3016CTTGATCCTT GCTGCTTCTT TTACATATGT TGGCACATCT TTCTCAAATG 3066CAGGCCATGC TCCATGCTTG GCGCTTGCTC AGCGTGGTTA AGTAATGGGA 3116GAATCTGAAA ACTAGGGGCC AGTGGTTTGT TTTGGGGACA AATTAGCACG 3166TAGTGATATT TCCCCCTAAA AATTATAACA AACAGATTCA TGATTTGAGA 3216TCCTTCTACA GGTGAGAAGT GGAAAAATTG TCACTATGAA GTTCTTTTTA 3266GGCTAAAGAT ACTTGGAACC ATAGAAGCGT TGTTAAAATA CTGCTTTCTT 3316TTGCTAAAAT ATTCTTTCTC ACATATTCAT ATTCTCCAG 3355GT GTT CCT GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT 3396AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT 3438ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA 3480AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA 3522GAG GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC 3564TTC TCA CCT TAG 3576GCATGCAGGT ACTGGCTTCA CTAACCAACC ATTCCTAACA TATGCCTGTA 3626GCTAAGAGCA TCTTTTTAAA AAATATTATT GGTAAACTAA ACAATTGTTA 3676 TCTTTTTACA TTAATAAGTA TTAAATTAAT CCAGTATACA GTTTTAAGAA 3726CCCTAAGTTA AACAGAAGTC AATGATGTCT AGATGCCTGT TCTTTAGATT 3776GTAGTGAGAC TACTTACTAC AGATGAGAAG TTGTTAGACT CGGGAGTAGA 3826GACCAGTAAA AGATCATGCA GTGAAATGTG GCCATGGAAA TCGCATATTG 3876TTCTTATAGT ACCTTTGAGA CAGCTGATAA CAGCTGACAA AAATAAGTGT 3926TTCAAGAAAG ATCACACGCC ATGGTTCACA TGCAAATTAT TATTTTGTCG 3976TTCTGATTTT TTTCATTTCT AGACCTGTGG TTTTAAAGAG ATGAAAATCT 4026CTTAAAATTT CCTTCATCTT TAATTTTCCT TAACTTTAGT TTTTTTCACT 4076TAGAATTCAA TTCAAATTCT TAATTCAATC TTAATTTTTA GATTTCTTAA 4126AATGTTTTTT AAAAAAAATG CAAATCTCAT TTTTAAGAGA TGAAAGCAGA 4176GTAACTGGGG GGCTTAGGGA ATCTGTAGGG TTGCGGTATA GCAATAGGGA 4226GTTCTGGTCT CTGAGAAGCA GTCAGAGAGA ATGGAAAACC AGGCCCTTGC 4276CAGTAGGTTA GTGAGGTTGA TATGATCAGA TTATGGACAC TCTCCAAATC 4326ATAAATACTC TAACAGCTAA GGATCTCTGA GGGAAACACA ACAGGGAAAT 4376ATTTTAGTTT CTCCTTGAGA AACAATGACA AGACATAAAA TTGGCAAGAA 4426AGTCAGGAGT GTATTCTAAT AAGTGTTGCT TATCTCTTAT TTTCTTCTAC 4476AGTTGCAAAG CCCAGAAGAA AGAAATGGAC AGCGGAAGAA GTGGTTGTTT 4526TTTTTTCCCC TTCATTAATT TTCTAGTTTT TAGTAATCCA GAAAATTTGA 4576TTTTGTTCTA AAGTTCATTA TGCAAAGATG TCACCAACAG ACTTCTGACT 4626GCATGGTGAA CTTTCATATG ATACATAGGA TTACACTTGT ACCTGTTAAA 4676AATAAAAGTT TGACTTGCAT AC 4698(2)SEQ ID NO.6的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.6Leu Pro Tyr Leu Gly Trp Leu Val Phe
5(2)SEQ ID NO.7的信息(i)序列特征:
(A)长度:2419bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(xi)序列描述:SEQ ID NO.7GGATCCAGGC CCTGCCAGGA AAAATATAAG GGCCCTGCGT GAGAACAGAG 50GGGGTCATCC ACTGCATGAG AGTGGGGATG TCACAGAGTC CAGCCCACCC 100TCCTGGTAGC ACTGAGAAGC CAGGGCTGTG CTTGCGGTCT GCACCCTGAG 150GGCCCGTGGA TTCCTCTTCC TGGAGCTCCA GGAACCAGGC AGTGAGGCCT 200TGGTCTGAGA CAGTATCCTC AGGTCACAGA GCAGAGGATG CACAGGGTGT 250GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300CAGGACACAT AGGACTCCAC AGAGTCTGGC CTCACCTCCC TACTGTCAGT 350CCTGTAGAAT CGACCTCTGC TGGCCGGCTG TACCCTGAGT ACCCTCTCAC 400TTCCTCCTTC AGGTTTTCAG GGGACAGGCC AACCCAGAGG ACAGGATTCC 450CTGGAGGCCA CAGAGGAGCA CCAAGGAGAA GATCTGTAAG TAGGCCTTTG 500TTAGAGTCTC CAAGGTTCAG TTCTCAGCTG AGGCCTCTCA CACACTCCCT 550CTCTCCCCAG GCCTGTGGGT CTTCATTGCC CAGCTCCTGC CCACACTCCT 600GCCTGCTGCC CTGACGAGAG TCATCATGTC TCTTGAGCAG AGGAGTCTGC 650ACTGCAAGCC TGAGGAAGCC CTTGAGGCCC AACAAGAGGC CCTGGGCCTG 700GTGTGTGTGC AGGCTGCCAC CTCCTCCTCC TCTCCTCTGG TCCTGGGCAC 750CCTGGAGGAG GTGCCCACTG CTGGGTCAAC AGATCCTCCC CAGAGTCCTC 800AGGGAGCCTC CGCCTTTCCC ACTACCATCA ACTTCACTCG ACAGAGGCAA 850CCCAGTGAGG GTTCCAGCAG CCGTGAAGAG GAGGGGCCAA GCACCTCTTG 900TATCCTGGAG TCCTTGTTCC GAGCAGTAAT CACTAAGAAG GTGGCTGATT 950TGGTTGGTTT TCTGCTCCTC AAATATCGAG CCAGGGAGCC AGTCACAAAG 1000GCAGAAATGC TGGAGAGTGT CATCAAAAAT TACAAGCACT GTTTTCCTGA 1050GATCTTCGGC AAAGCCTCTG AGTCCTTGCA GCTGGTCTTT GGCATTGACG 1100TGAAGGAAGC AGACCCCACC GGCCACTCCT ATGTCCTTGT CACCTGCCTA 1150GGTCTCTCCT ATGATGGCCT GCTGGGTGAT AATCAGATCA TGCCCAAGAC 1200AGGCTTCCTG ATAATTGTCC TGGTCATGAT TGCAATGGAG GGCGGCCATG 1250CTCCTGAGGA GGAAATCTGG GAGGAGCTGA GTGTGATGGA GGTGTATGAT 1300GGGAGGGAGC ACAGTGCCTA TGGGGAGCCC AGGAAGCTGC TCACCCAAGA 1350 TTTGGTGCAG GAAAAGTACC TGGAGTACGG CAGGTGCCGG ACAGTGATCC 1400CGCACGCTAT GAGTTCCTGT GGGGTCCAAG GGCCCTCGCT GAAACCAGCT 1450ATGTGAAAGT CCTTGAGTAT GTGATCAAGG TCAGTGCAAG AGTTCGCTTT 1500TTCTTCCCAT CCCTGCGTGA AGCAGCTTTG AGAGAGGAGG AAGAGGGAGT 1550CTGAGCATGA GTTGCAGCCA AGGCCAGTGG GAGGGGGACT GGGCCAGTGC 1600ACCTTCCAGG GCCGCGTCCA GCAGCTTCCC CTGCCTCGTG TGACATGAGG 1650CCCATTCTTC ACTCTGAAGA GAGCGGTCAG TGTTCTCAGT AGTAGGTTTC 1700TGTTCTATTG GGTGACTTGG AGATTTATCT TTGTTCTCTT TTGGAATTGT 1750TCAAATGTTT TTTTTTAAGG GATGGTTGAA TGAACTTCAG CATCCAAGTT 1800TATGAATGAC AGCAGTCACA CAGTTCTGTG TATATAGTTT AAGGGTAAGA 1850GTCTTGTGTT TTATTCAGAT TGGGAAATCC ATTCTATTTT GTGAATTGGG 1900ATAATAACAG CAGTGGAATA AGTACTTAGA AATGTGAAAA ATGAGCAGTA 1950AAATAGATGA GATAAAGAAC TAAAGAAATT AAGAGATAGT CAATTCTTGC 2000CTTATACCTC AGTCTATTCT GTAAAATTTT TAAAGATATA TGCATACCTG 2050GATTTCCTTG GCTTCTTTGA GAATGTAAGA GAAATTAAAT CTGAATAAAG 2100AATTCTTCCT GTTCACTGGC TCTTTTCTTC TCCATGCACT GAGCATCTGC 2150TTTTTGGAAG GCCCTGGGTT AGTAGTGGAG ATGCTAAGGT AAGCCAGACT 2200CATACCCACC CATAGGGTCG TAGAGTCTAG GAGCTGCAGT CACGTAATCG 2250AGGTGGCAAG ATGTCCTCTA AAGATGTAGG GAAAAGTGAG AGAGGGGTGA 2300GGGTGTGGGG CTCCGGGTGA GAGTGGTGGA GTGTCAATGC CCTGAGCTGG 2350GGCATTTTGG GCTTTGGGAA ACTGCAGTTC CTTCTGGGGG AGCTGATTGT 2400AATGATCTTG GGTGGATCC 2419(2)SEQ ID NO.8的信息(i)序列特征:
(A)长度:5674bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-1基因(xi)序列描述:SEQ ID NO.8CCCGGGGCAC CACTGGCATC CCTCCCCCTA CCACCCCCAA TCCCTCCCTT 50TACGCCACCC ATCCAAACAT CTTCACGCTC ACCCCCAGCC CAAGCCAGGC 100AGAATCCGGT TCCACCCCTG CTCTCAACCC AGGGAAGCCC AGGTGCCCAG 150ATGTGACGCC ACTGACTTGA GCATTAGTGG TTAGAGAGAA GCGAGGTTTT 200CGGTCTGAGG GGCGGCTTGA GATCGGTGGA GGGAAGCGGG CCCAGCTCTG 250TAAGGAGGCA AGGTGACATG CTGAGGGAGG ACTGAGGACC CACTTACCCC 300AGATAGAGGA CCCCAAATAA TCCCTTCATG CCAGTCCTGG ACCATCTGGT 350GGTGGACTTC TCAGGCTGGG CCACCCCCAG CCCCCTTGCT GCTTAAACCA 400CTGGGGACTC GAAGTCAGAG CTCCGTGTGA TCAGGGAAGG GCTGCTTAGG 450AGAGGGCAGC GTCCAGGCTC TGCCAGACAT CATGCTCAGG ATTCTCAAGG 500AGGGCTGAGG GTCCCTAAGA CCCCACTCCC GTGACCCAAC CCCCACTCCA 550ATGCTCACTC CCGTGACCCA ACCCCCTCTT CATTGTCATT CCAACCCCCA 600CCCCACATCC CCCACCCCAT CCCTCAACCC TGATGCCCAT CCGCCCAGCC 650ATTCCACCCT CACCCCCACC CCCACCCCCA CGCCCACTCC CACCCCCACC 700CAGGCAGGAT CCGGTTCCCG CCAGGAAACA TCCGGGTGCC CGGATGTGAC 750GCCACTGACT TGCGCATTGT GGGGCAGAGA GAAGCGAGGT TTCCATTCTG 800AGGGACGGCG TAGAGTTCGG CCGAAGGAAC CTGACCCAGG CTCTGTGAGG 850AGGCAAGGTG AGAGGCTGAG GGAGGACTGA GGACCCCGCC ACTCCAAATA 900GAGAGCCCCA AATATTCCAG CCCCGCCCTT GCTGCCAGCC CTGGCCCACC 950CGCGGGAAGA CGTCTCAGCC TGGGCTGCCC CCAGACCCCT GCTCCAAAAG 1000CCTTGAGAGA CACCAGGTTC TTCTCCCCAA GCTCTGGAAT CAGAGGTTGC 1050TGTGACCAGG GCAGGACTGG TTAGGAGAGG GCAGGGCACA GGCTCTGCCA 1100GGCATCAAGA TCAGCACCCA AGAGGGAGGG CTGTGGGCCC CCAAGACTGC 1150ACTCCAATCC CCACTCCCAC CCCATTCGCA TTCCCATTCC CCACCCAACC 1200CCCATCTCCT CAGCTACACC TCCACCCCCA TCCCTACTCC TACTCCGTCA 1250CCTGACCACC ACCCTCCAGC CCCAGCACCA GCCCCAACCC TTCTGCCACC 1300TCACCCTCAC TGCCCCCAAC CCCACCCTCA TCTCTCTCAT GTGCCCCACT 1350CCCATCGCCT CCCCCATTCT GGCAGAATCC GGTTTGCCCC TGCTCTCAAC 1400CCAGGGAAGC CCTGGTAGGC CCGATGTGAA ACCACTGACT TGAACCTCAC 1450AGATCTGAGA GAAGCCAGGT TCATTTAATG GTTCTGAGGG GCGGCTTGAG 1500ATCCACTGAG GGGAGTGGTT TTAGGCTCTG TGAGGAGGCA AGGTGAGATG 1550CTGAGGGAGG ACTGAGGAGG CACACACCCC AGGTAGATGG CCCCAAAATG 1600ATCCAGTACC ACCCCTGCTG CCAGCCCTGG ACCACCCGGC CAGGACAGAT 1650GTCTCAGCTG GACCACCCCC CGTCCCGTCC CACTGCCACT TAACCCACAG 1700GGCAATCTGT AGTCATAGCT TATGTGACCG GGGCAGGGTT GGTCAGGAGA 1750GGCAGGGCCC AGGCATCAAG GTCCAGCATC CGCCCGGCAT TAGGGTCAGG 1800ACCCTGGGAG GGAACTGAGG GTTCCCCACC CACACCTGTC TCCTCATCTC 1850CACCGCCACC CCACTCACAT TCCCATACCT ACCCCCTACC CCCAACCTCA 1900TCTTGTCAGA ATCCCTGCTG TCAACCCACG GAAGCCACGG GAATGGCGGC 1950CAGGCACTCG GATCTTGACG TCCCCATCCA GGGTCTGATG GAGGGAAGGG 2000GCTTGAACAG GGCCTCAGGG GAGCAGAGGG AGGGCCCTAC TGCGAGATGA 2050GGGAGGCCTC AGAGGACCCA GCACCCTAGG ACACCGCACC CCTGTCTGAG 2100ACTGAGGCTG CCACTTCTGG CCTCAAGAAT CAGAACGATG GGGACTCAGA 2150TTGCATGGGG GTGGGACCCA GGCCTGCAAG GCTTACGCGG AGGAAGAGGA 2200GGGAGGACTC AGGGGACCTT GGAATCCAGA TCAGTGTGGA CCTCGGCCCT 2250GAGAGGTCCA GGGCACGGTG GCCACATATG GCCCATATTT CCTGCATCTT 2300TGAGGTGACA GGACAGAGCT GTGGTCTGAG AAGTGGGGCC TCAGGTCAAC 2350AGAGGGAGGA GTTCCAGGAT CCATATGGCC CAAGATGTGC CCCCTTCATG 2400AGGACTGGGG ATATCCCCGG CTCAGAAAGA AGGGACTCCA CACAGTCTGG 2450CTGTCCCCTT TTAGTAGCTC TAGGGGGACC AGATCAGGGA TGGCGGTATG 2500TTCCATTCTC ACTTGTACCA CAGGCAGGAA GTTGGGGGGC CCTCAGGGAG 2550ATGGGGTCTT GGGGTAAAGG GGGGATGTCT ACTCATGTCA GGGAATTGGG 2600GGTTGAGGAA GCACAGGCGC TGGCAGGAAT AAAGATGAGT GAGACAGACA 2650AGGCTATTGG AATCCACACC CCAGAACCAA AGGGGTCAGC CCTGGACACC 2700TCACCCAGGA TGTGGCTTCT TTTTCACTCC TGTTTCCAGA TCTGGGGCAG 2750GTGAGGACCT CATTCTCAGA GGGTGACTCA GGTCAACGTA GGGACCCCCA 2800TCTGGTCTAA AGACAGAGCG GTCCCAGGAT CTGCCATGCG TTCGGGTGAG 2850GAACATGAGG GAGGACTGAG GGTACCCCAG GACCAGAACA CTGAGGGAGA 2900CTGCACAGAA ATCAGCCCTG CCCCTGCTGT CACCCCAGAG AGCATGGGCT 2950GGGCCGTCTG CCGAGGTCCT TCCGTTATCC TGGGATCATT GATGTCAGGG 3000ACGGGGAGGC CTTGGTCTGA GAAGGCTGCG CTCAGGTCAG TAGAGGGAGC 3050GTCCCAGGCC CTGCCAGGAG TCAAGGTGAG GACCAAGCGG GCACCTCACC 3100CAGGACACAT TAATTCCAAT GAATTTTGAT ATCTCTTGCT GCCCTTCCCC 3150AAGGACCTAG GCACGTGTGG CCAGATGTTT GTCCCCTCCT GTCCTTCCAT 3200TCCTTATCAT GGATGTGAAC TCTTGATTTG GATTTCTCAG ACCAGCAAAA 3250GGGCAGGATC CAGGCCCTGC CAGGAAAAAT ATAAGGGCCC TGCGTGAGAA 3300CAGAGGGGGT CATCCACTGC ATGAGAGTGG GGATGTCACA GAGTCCAGCC 3350CACCCTCCTG GTAGCACTGA GAAGCCAGGG CTGTGCTTGC GGTCTGCACC 3400CTGAGGGCCC GTGGATTCCT CTTCCTGGAG CTCCAGGAAC CAGGCAGTGA 3450GGCCTTGGTC TGAGACAGTA TCCTCAGGTC ACAGAGCAGA GGATGCACAG 3500GGTGTGCCAG CAGTGAATGT TTGCCCTGAA TGCACACCAA GGGCCCCACC 3550TGCCACAGGA CACATAGGAC TCCACAGAGT CTGGCCTCAC CTCCCTACTG 3600TCAGTCCTGT AGAATCGACC TCTGCTGGCC GGCTGTACCC TGAGTACCCT 3650CTCACTTCCT CCTTCAGGTT TTCAGGGGAC AGGCCAACCC AGAGGACAGG 3700ATTCCCTGGA GGCCACAGAG GAGCACCAAG GAGAAGATCT GTAAGTAGGC 3750CTTTGTTAGA GTCTCCAAGG TTCAGTTCTC AGCTGAGGCC TCTCACACAC 3800TCCCTCTCTC CCCAGGCCTG TGGGTCTTCA TTGCCCAGCT CCTGCCCACA 3850CTCCTGCCTG CTGCCCTGAC GAGAGTCATC 3880ATG TCT CTT GAG CAG AGG AGT CTG CAC TGC AAG CCT GAG GAA 3922GCC CTT GAG GCC CAA CAA GAG GCC CTG GGC CTG GTG TGT GTG 3964CAG GCT GCC ACC TCC TCC TCC TCT CCT CTG GTC CTG GGC ACC 4006CTG GAG GAG GTG CCC ACT GCT GGG TCA ACA GAT CCT CCC CAG 4048AGT CCT CAG GGA GCC TCC GCC TTT CCC ACT ACC ATC AAC TTC 4090ACT CGA CAG AGG CAA CCC AGT GAG GGT TCC AGC AGC CGT GAA 4132GAG GAG GGG CCA AGC ACC TCT TGT ATC CTG GAG TCC TTG TTC 4174CGA GCA GTA ATC ACT AAG AAG GTG GCT GAT TTG GTT GGT TTT 4216CTG CTC CTC AAA TAT CGA GCC AGG GAG CCA GTC ACA AAG GCA 4258GAA ATG CTG GAG AGT GTC ATC AAA AAT TAC AAG CAC TGT TTT 4300CCT GAG ATC TTC GGC AAA GCC TCT GAG TCC TTG CAG CTG GTC 4342TTT GGC ATT GAC GTG AAG GAA GCA GAC CCC ACC GGC CAC TCC 4384TAT GTC CTT GTC ACC TGC CTA GGT CTC TCC TAT GAT GGC CTG 4426CTG GGT GAT AAT CAG ATC ATG CCC AAG ACA GGC TTC CTG ATA 4468ATT GTC CTG GTC ATG ATT GCA ATG GAG GGC GGC CAT GCT CCT 4510GAG GAG GAA ATC TGG GAG GAG CTG AGT GTG ATG GAG GTG TAT 4552GAT GGG AGG GAG CAC AGT GCC TAT GGG GAG CCC AGG AAG CTG 4594CTC ACC CAA GAT TTG GTG CAG GAA AAG TAC CTG GAG TAC GGC 4636AGG TGC CGG ACA GTG ATC CCG CAC GCT ATG AGT TCC TGT GGG 4678GTC CAA GGG CCC TCG CTG AAA CCA GCT ATG TGA 4711AAGTCCTTGA GTATGTGATC AAGGTCAGTG CAAGAGTTC 4750GCTTTTTCTT CCCATCCCTG CGTGAAGCAG CTTTGAGAGA GGAGGAAGAG 4800GGAGTCTGAG CATGAGTTGC AGCCAAGGCC AGTGGGAGGG GGACTGGGCC 4850AGTGCACCTT CCAGGGCCGC GTCCAGCAGC TTCCCCTGCC TCGTGTGACA 4900TGAGGCCCAT TCTTCACTCT GAAGAGAGCG GTCAGTGTTC TCAGTAGTAG 4950GTTTCTGTTC TATTGGGTGA CTTGGAGATT TATCTTTGTT CTCTTTTGGA 5000ATTGTTCAAA TGTTTTTTTT TAAGGGATGG TTGAATGAAC TTCAGCATCC 5050AAGTTTATGA ATGACAGCAG TCACACAGTT CTGTGTATAT AGTTTAAGGG 5100TAAGAGTCTT GTGTTTTATT CAGATTGGGA AATCCATTCT ATTTTGTGAA 5150TTGGGATAAT AACAGCAGTG GAATAAGTAC TTAGAAATGT GAAAAATGAG 5200CAGTAAAATA GATGAGATAA AGAACTAAAG AAATTAAGAG ATAGTCAATT 5250CTTGCCTTAT ACCTCAGTCT ATTCTGTAAA ATTTTTAAAG ATATATGCAT 5300ACCTGGATTT CCTTGGCTTC TTTGAGAATG TAAGAGAAAT TAAATCTGAA 5350 TAAAGAATTC TTCCTGTTCA CTGGCTCTTT TCTTCTCCAT GCACTGAGCA 5400TCTGCTTTTT GGAAGGCCCT GGGTTAGTAG TGGAGATGCT AAGGTAAGCC 5450AGACTCATAC CCACCCATAG GGTCGTAGAG TCTAGGAGCT GCAGTCACGT 5500AATCGAGGTG GCAAGATGTC CTCTAAAGAT GTAGGGAAAA GTGAGAGAGG 5550GGTGAGGGTG TGGGGCTCCG GGTGAGAGTG GTGGAGTGTC AATGCCCTGA 5600GCTGGGGCAT TTTGGGCTTT GGGAAACTGC AGTTCCTTCT GGGGGAGCTG 5650ATTGTAATGA TCTTGGGTGG ATCC 5674(2)SEQ ID NO.9的信息(i)序列特征:
(A)长度:4157bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-2基因(xi)序列描述:SEQ ID NO.9CCCATCCAGA TCCCCATCCG GGCAGAATCC GGTTCCACCC TTGCCGTGAA 50CCCAGGGAAG TCACGGGCCC GGATGTGACG CCACTGACTT GCACATTGGA 100GGTCAGAGGA CAGCGAGATT CTCGCCCTGA GCAACGGCCT GACGTCGGCG 150GAGGGAAGCA GGCGCAGGCT CCGTGAGGAG GCAAGGTAAG ACGCCGAGGG 200AGGACTGAGG CGGGCCTCAC CCCAGACAGA GGGCCCCCAA TTAATCCAGC 250GCTGCCTCTG CTGCCGGGCC TGGACCACCC TGCAGGGGAA GACTTCTCAG 300GCTCAGTCGC CACCACCTCA CCCCGCCACC CCCCGCCGCT TTAACCGCAG 350GGAACTCTGG CGTAAGAGCT TTGTGTGACC AGGGCAGGGC TGGTTAGAAG 400TGCTCAGGGC CCAGACTCAG CCAGGAATCA AGGTCAGGAC CCCAAGAGGG 450GACTGAGGGC AACCCACCCC CTACCCTCAC TACCAATCCC ATCCCCCAAC 500ACCAACCCCA CCCCCATCCC TCAAACACCA ACCCCACCCC CAAACCCCAT 550TCCCATCTCC TCCCCCACCA CCATCCTGGC AGAATCCGGC TTTGCCCCTG 600CAATCAACCC ACGGAAGCTC CGGGAATGGC GGCCAAGCAC GCGGATCCTG 650ACGTTCACAT GTACGGCTAA GGGAGGGAAG GGGTTGGGTC TCGTGAGTAT 700GGCCTTTGGG ATGCAGAGGA AGGGCCCAGG CCTCCTGGAA GACAGTGGAG 750TCCTTAGGGG ACCCAGCATG CCAGGACAGG GGGCCCACTG TACCCCTGTC 800TCAAACTGAG CCACCTTTTC ATTCAGCCGA GGGAATCCTA GGGATGCAGA 850CCCACTTCAG GGGGTTGGGG CCCAGCCTGC GAGGAGTCAA GGGGAGGAAG 900AAGAGGGAGG ACTGAGGGGA CCTTGGAGTC CAGATCAGTG GCAACCTTGG 950GCTGGGGGAT CCTGGGCACA GTGGCCGAAT GTGCCCCGTG CTCATTGCAC 1000CTTCAGGGTG ACAGAGAGTT GAGGGCTGTG GTCTGAGGGC TGGGACTTCA 1050GGTCAGCAGA GGGAGGAATC CCAGGATCTG CCGGACCCAA GGTGTGCCCC 1100CTTCATGAGG ACTCCCCATA CCCCCGGCCC AGAAAGAAGG GATGCCACAG 1150AGTCTGGAAG TAAATTGTTC TTAGCTCTGG GGGAACCTGA TCAGGGATGG 1200CCCTAAGTGA CAATCTCATT TGTACCACAG GCAGGAGGTT GGGGAACCCT 1250CAGGGAGATA AGGTGTTGGT GTAAAGAGGA GCTGTCTGCT CATTTCAGGG 1300GGTTCCCCCT TGAGAAAGGG CAGTCCCTGG CAGGAGTAAA GATGAGTAAC 1350CCACAGGAGG CCATCATAAC GTTCACCCTA GAACCAAAGG GGTCAGCCCT 1400GGACAACGCA CGTGGGGTAA CAGGATGTGG CCCCTCCTCA CTTGTCTTTC 1450CAGATCTCAG GGAGTTGATG ACCTTGTTTT CAGAAGGTGA CTCAGTCAAC 1500ACAGGGGCCC CTCTGGTCGA CAGATGCAGT GGTTCTAGGA TCTGCCAAGC 1550ATCCAGGTGG AGAGCCTGAG GTAGGATTGA GGGTACCCCT GGGCCAGAAT 1600GCAGCAAGGG GGCCCCATAG AAATCTGCCC TGCCCCTGCG GTTACTTCAG 1650AGACCCTGGG CAGGGCTGTC AGCTGAAGTC CCTCCATTAT CTGGGATCTT 1700TGATGTCAGG GAAGGGGAGG CCTTGGTCTG AAGGGGCTGG AGTCAGGTCA 1750GTAGAGGGAG GGTCTCAGGC CCTGCCAGGA GTGGACGTGA GGACCAAGCG 1800GACTCGTCAC CCAGGACACC TGGACTCCAA TGAATTTGAC ATCTCTCGTT 1850GTCCTTCGCG GAGGACCTGG TCACGTATGG CCAGATGTGG GTCCCCTCTA 1900TCTCCTTCTG TACCATATCA GGGATGTGAG TTCTTGACAT GAGAGATTCT 1950CAAGCCAGCA AAAGGGTGGG ATTAGGCCCT ACAAGGAGAA AGGTGAGGGC 2000CCTGAGTGAG CACAGAGGGG ACCCTCCACC CAAGTAGAGT GGGGACCTCA 2050CGGAGTCTGG CCAACCCTGC TGAGACTTCT GGGAATCCGT GGCTGTGCTT 2100GCAGTCTGCA CACTGAAGGC CCGTGCATTC CTCTCCCAGG AATCAGGAGC 2150TCCAGGAACC AGGCAGTGAG GCCTTGGTCT GAGTCAGTGC CTCAGGTCAC 2200AGAGCAGAGG GGACGCAGAC AGTGCCAACA CTGAAGGTTT GCCTGGAATG 2250CACACCAAGG GCCCCACCCG CCCAGAACAA ATGGGACTCC AGAGGGCCTG 2300GCCTCACCCT CCCTATTCTC AGTCCTGCAG CCTGAGCATG TGCTGGCCGG 2350CTGTACCCTG AGGTGCCCTC CCACTTCCTC CTTCAGGTTC TGAGGGGGAC 2400AGGCTGACAA GTAGGACCCG AGGCACTGGA GGAGCATTGA AGGAGAAGAT 2450CTGTAAGTAA GCCTTTGTCA GAGCCTCCAA GGTTCAGTTC AGTTCTCACC 2500TAAGGCCTCA CACACGCTCC TTCTCTCCCC AGGCCTGTGG GTCTTCATTG 2550CCCAGCTCCT GCCCGCACTC CTGCCTGCTG CCCTGACCAG AGTCATC 2597ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA 2639GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG GTG GGT GCG 2681CAG GCT CCT GCT ACT GAG GAG CAG CAG ACC GCT TCT TCC TCT 2723TCT ACT CTA GTG GAA GTT ACC CTG GGG GAG GTG CCT GCT GCC 2765GAC TCA CCG AGT CCT CCC CAC AGT CCT CAG GGA GCC TCC AGC 2807TTC TCG ACT ACC ATC AAC TAC ACT CTT TGG AGA CAA TCC GAT 2849GAG GGC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGA ATG TTT 2891CCC GAC CTG GAG TCC GAG TTC CAA GCA GCA ATC AGT AGG AAG 2933ATG GTT GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC 2975AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGT GTC CTC 3017AGA AAT TGC CAG GAC TTC TTT CCC GTG ATC TTC AGC AAA GCC 3059TCC GAG TAC TTG CAG CTG GTC TTT GGC ATC GAG GTG GTG GAA 3101GTG GTC CCC ATC AGC CAC TTG TAC ATC CTT GTC ACC TGC CTG 3143GGC CTC TCC TAC GAT GGC CTG CTG GGC GAC AAT CAG GTC ATG 3185CCC AAG ACA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA 3227ATA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG 3269CTG AGT ATG TTG GAG GTG TTT GAG GGG AGG GAG GAC AGT GTC 3311TTC GCA CAT CCC AGG AAG CTG CTC ATG CAA GAT CTG GTG CAG 3353GAA AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT 3395GCA TGC TAC GAG TTC CTG TGG GGT CCA AGG GCC CTC ATT GAA 3437ACC AGC TAT GTG AAA GTC CTG CAC CAT ACA CTA AAG ATC GGT 3479GGA GAA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAA CGG GCT 3521TTG AGA GAG GGA GAA GAG TGA 3542GTCTCAGCAC ATGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT 3592GCACCTTCCA GGGCCCCATC CATTAGCTTC CACTGCCTCG TGTGATATGA 3642GGCCCATTCC TGCCTCTTTG AAGAGAGCAG TCAGCATTCT TAGCAGTGAG 3692TTTCTGTTCT GTTGGATGAC TTTGAGATTT ATCTTTCTTT CCTGTTGGAA 3742TTGTTCAAAT GTTCCTTTTA ACAAATGGTT GGATGAACTT CAGCATCCAA 3792GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGGG 3842TAAGAGTCCT GTTTTTTATT CAGATTGGGA AATCCATTCC ATTTTGTGAG 3892TTGTCACATA ATAACAGCAG TGGAATATGT ATTTGCCTAT ATTGTGAACG 3942AATTAGCAGT AAAATACATG ATACAAGGAA CTCAAAAGAT AGTTAATTCT 3992TGCCTTATAC CTCAGTCTAT TATGTAAAAT TAAAAATATG TGTATGTTTT 4042TGCTTCTTTG AGAATGCAAA AGAAATTAAA TCTGAATAAA TTCTTCCTGT 4092TCACTGGCTC ATTTCTTTAC CATTCACTCA GCATCTGCTC TGTGGAAGGC 4142CCTGGTAGTA GTGGG 4157(2)SEQ ID NO.10的信息(i)序列特征:
(A)长度:662bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-21基因(xi)序列描述:SEQ ID NO.10GGATCCCCAT GGATCCAGGA AGAATCCAGT TCCACCCCTG CTGTGAACCC 50AGGGAAGTCA CGGGGCCGGA TGTGACGCCA CTGACTTGCG CGTTGGAGGT 100CAGAGAACAG CGAGATTCTC GCCCTGAGCA ACGGCCTGAC GTCGGCGGAG 150GGAAGCAGGC GCAGGCTCCG TGAGGAGGCA AGGTAAGATG CCGAGGGAGG 200ACTGAGGCGG GCCTCACCCC AGACAGAGGG CCCCCAATAA TCCAGCGCTG 250CCTCTGCTGC CAGGCCTGGA CCACCCTGCA GGGGAAGACT TCTCAGGCTC 300AGTCGCCACC ACCTCACCCC GCCACCCCCC GCCGCTTTAA CCGCAGGGAA 350CTCTGGTGTA AGAGCTTTGT GTGACCAGGG CAGGGCTGGT TAGAAGTGCT 400CAGGGCCCAG ACTCAGCCAG GAATCAAGGT CAGGACCCCA AGAGGGGACT 450GAGGGTAACC CCCCCGCACC CCCACCACCA TTCCCATCCC CCAACACCAA 500CCCCACCCCC ATCCCCCAAC ACCAAACCCA CCACCATCGC TCAAACATCA 550ACGGCACCCC CAAACCCCGA TTCCCATCCC CACCCATCCT GGCAGAATCG 600GAGCTTTGCC CCTGCAATCA ACCCACGGAA GCTCCGGGAA TGGCGGCCAA 650GCACGCGGAT CC 662(2)SEQ ID NO.11的信息(i)序列特征:
(A)长度:1640bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:cDNA至mRNA(ix)特征:
(A)名称/关键:cDNA MAGE-3(xi)序列描述:SEQ ID NO.11GCCGCGAGGG AAGCCGGCCC AGGCTCGGTG AGGAGGCAAG GTTCTGAGGG 50GACAGGCTGA CCTGGAGGAC CAGAGGCCCC CGGAGGAGCA CTGAAGGAGA 100AGATCTGCCA GTGGGTCTCC ATTGCCCAGC TCCTGCCCAC ACTCCCGCCT 150GTTGCCCTGA CCAGAGTCAT C 171ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA 213GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG GTG GGT GCG 255CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCC TCC TCT 297TCT ACT CTA GTT GAA GTC ACC CTG GGG GAG GTG CCT GCT GCC 339GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA GCC TCC AGC 381CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC CAA TCC TAT 423GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGC ACC TTC 465CCT GAC CTG GAG TCC GAG TTC CAA GCA GCA CTC AGT AGG AAG 507GTG GCC GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC 549AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GGG AGT GTC GTC 591GGA AAT TGG CAG TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT 633TCC AGT TCC TTG CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA 675GTG GAC CCC ATC GGC CAC TTG TAC ATC TTT GCC ACC TGC CTG 717GGC CTC TCC TAC GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG 759CCC AAG GCA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA 801AGA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG 843CTG AGT GTG TTA GAG GTG TTT GAG GGG AGG GAA GAC AGT ATG 885TTG GGG GAT CCC AAG AAG CTG CTC ACC CAA CAT TTC GTG CAG 927GAA AAC TAC CTG GAG TAC CGG CAG GTC CCC GGC AGT GAT CCT 969GCA TGT TAT GAA TTC CTG TGG GGT CCA AGG GCC CTC GTT GAA 1011ACC AGC.TAT GTG AAA GTC CTG CAC CAT ATG GTA AAG ATC AGT 1053GGA GGA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAG TGG GTT 1095TTG AGA GAG GGG GAA GAG TGA 1116GTCTGAGCAC GAGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT 1166GCACCTTCCG GGGCCGCATC CCTTAGTTTC CACTGCCTCC TGTGACGTGA 1216GGCCCATTCT TCACTCTTTG AAGCGAGCAG TCAGCATTCT TAGTAGTGGG 1266TTTCTGTTCT GTTGGATGAC TTTGAGATTA TTCTTTGTTT CCTGTTGGAG 1316TTGTTCAAAT GTTCCTTTTA ACGGATGGTT GAATGAGCGT CAGCATCCAG 1366GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGAG 1416TAAGAGTCTT GttTTTTACT CAAATTgGGA AATCCATTCC ATTTTGTGAA 1466TTGTGACATA ATAATAGCAG TGGTAAAAGT ATTTGCTTAA AATTGTGAGC 1516GAATTAGCAA TAACATACAT GAGATAACTC AAGAAATCAA AAGATAGTTG 1566ATTCTTGCCT TGTACCTCAA TCTATTCTGT AAAATTAAAC AAATATGCAA 1616ACCAGGATTT CCTTGACTTC TTTG 1640(2)SEQ ID NO.12的信息(i)序列特征:
(A)长度:943bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-31基因(xi)序列描述:SEQ ID NO.12
GGATCCTCCA CCCCAGTAGA GTGGGGACCT CACAGAGTCT GGCCAACCCT 50
CCTGACAGTT CTGGGAATCC GTGGCTGCGT TTGCTGTCTG CACATTGGGG 100
GCCCGTGGAT TCCTCTCCCA GGAATCAGGA GCTCCAGGAA CAAGGCAGTG 150
AGGACTTGGT CTGAGGCAGT GTCCTCAGGT CACAGAGTAG AGGGGgCTCA 200
GATAGTGCCA ACGGTGAAGG TTTGCCTTGG ATTCAAACCA AGGGCCCCAC 250
CTGCCCCAGA ACACATGGAC TCCAGAGCGC CTGGCCTCAC CCTCAATACT 300
TTCAGTCCTG CAGCCTCAGC ATGCGCTGGC CGGATGTACC CTGAGGTGCC 350
CTCTCACTTC CTCCTTCAGG TTCTGAGGGG ACAGGCTGAC CTGGAGGACC 400
AGAGGCCCCC GGAGGAGCAC TGAAGGAGAA GATCTGTAAG TAAGCCTTTG 450
TTAGAGCCTC CAAGGTTCCA TTCAGTACTC AGCTGAGGTC TCTCACATGC 500
TCCCTCTCTC CCCAGGCCAG TGGGTCTCCA TTGCCCAGCT CCTGCCCACA 550
CTCCCGCCTG TTGCCCTGAC CAGAGTCATC 580
ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA 622
GGC CTT GAG GCC CGA GGA GAg GCC CTG GGC CTG GTG GGT GCG 664
CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCC TCC TCT 706
TCT AGT GTA GTT GAA GTC ACC CTG GGG GAG GTG CCT GCT GCC 748
GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA GCC TCC AGC 790
CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC CAA TCC TAT 832
GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGC ACC TTC 874
CCT GAC CTG GAG TCT GAG TTC CAA GCA GCA CTC AGT AGG AAG 916
GTG GCC AAG TTG GTT CAT TTT CTG CTC 943(2)SEQ ID NO.13的信息(i)序列特征:
(A)长度:2531bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-4基因(xi)序列描述:SEQ ID NO.13GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG 50GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC 100TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG 150GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT 200TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT 250GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT 350CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA 400CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC 450TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT 500TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC 550TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG 600CCTGCTGCCC TGACCAGAGT CATC 624ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 666GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCA 708CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC 750TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT 792GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT 834GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC 876AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC 918TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC 960AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA 1002GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC 1044ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA 1086GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG 1128GAA GTG GAC CCC GCC AGC AAC ACC TAC ACC CTT GTC ACC TGC 1170CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC 1212TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT 1254GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG 1296GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT 1338GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG 1380CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT 1422CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT 1464GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC 1506AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA 1548GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA 1578GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC 1628ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC 1678CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT 1728TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT 1778GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT 1828TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG 1878AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG 1928GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT 1978GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA 2028GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG 2078CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA 2128ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC 2178AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA 2228GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT 2278CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT 2328GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA 2378AACTGCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC 2428AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC 2478TCTGAGCAGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528GGG 2531(2)SEQ ID NO.14的信息(i)序列特征:
(A)长度:2531bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-41基因(xi)序列描述:SEQ ID NO.14GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG 50GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC 100TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG 150GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT 200TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT 250GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT 350CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA 400CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC 450TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT 500TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC 550TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG 600CCTGCTGCCC TGAGCAGAGT CATC 624ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 666GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCG 708CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC 750TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT 792GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT 834GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC 876AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC 918TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC 960AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA 1002GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC 1044ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA 1086GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG 1128GAA GTG GAC CCC ACC AGC AAC ACC TAC ACC CTT GTC ACC TGC 1170CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC 1212TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT 1254GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG 1296GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT 1338GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG 1380CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT 1422CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT 1464GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC 1506AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA 1548GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA 1578GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC 1628ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC 1678CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT 1728TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT 1778GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT 1828TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG 1878AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG 1928GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT 1978GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA 2028GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG 2078CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA 2128ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC 2178AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA 2228GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT 2278CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT 2328GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA 2378AACTCCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC 2428AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC 2478TCTGAGCGGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528GGG 2531(2)SEQ ID NO.15的信息(i)序列特征:
(A)长度:1068bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:cDNA至mRNA(ix)特征:
(A)名称/关键:cDNA MAGE-4(xi)序列描述:SEQ ID NO.15
G GGG CCA AGC ACC TCG CCT GAC GCA GAG TCC TTG TTC CGA 40GAA GCA CTC AGT AAC AAG GTG GAT GAG TTG GCT CAT TTT CTG 82CTC CGC AAG TAT CGA GCC AAG GAG CTG GTC ACA AAG GCA GAA 124ATG CTG GAG AGA GTC ATC AAA AAT TAC AAG CGC TGC TTT CCT 166GTG ATC TTC GGC AAA GCC TCC GAG TCC CTG AAG ATG ATC TTT 208GGC ATT GAC GTG AAG GAA GTG GAC CCC GCC AGC AAC ACC TAC 250ACC CTT GTC ACC TGC CTG GGC CTT TCC TAT GAT GGC CTG CTG 292GGT AAT AAT CAG ATC TTT CCC AAG ACA GGC CTT CTG ATA ATC 334GTC CTG GGC ACA ATT GCA ATG GAG GGC GAC AGC GCC TCT GAG 376GAG GAA ATC TGG GAG GAG CTG GGT GTG ATG GGG GTG TAT GAT 418GGG AGG GAG CAC ACT GTC TAT GGG GAG CCC AGG AAA CTG CTC 460ACC CAA GAT TGG GTG CAG GAA AAC TAC CTG GAG TAC CGG CAG 502GTA CCC GGC AGT AAT CCT GCG CGC TAT GAG TTC CTG TGG GGT 544CCA AGG GCT CTG GCT GAA ACC AGC TAT GTG AAA GTC CTG GAG 586CAT GTG GTC AGG GTC AAT GCA AGA GTT CGC ATT GCC TAC CCA 628TCC CTG CGT GAA GCA GCT TTG TTA GAG GAG GAA GAG GGA GTC 670TGAGCATGAG TTGCAGCCAG GGCTGTGGGG AAGGGGCAGG GCTGGGCCAG 720TGCATCTAAC AGCCCTGTGC AGCAGCTTCC CTTGCCTCGT GTAACATGAG 770GCCCATTCTT CACTCTGTTT GAAGAAAATA GTCAGTGTTC TTAGTAGTGG 820GTTTCTATTT TGTTGGATGA CTTGGAGATT TATCTCTGTT TCCTTTTACA 870ATTGTTGAAA TGTTCCTTTT AATGGATGGT TGAATTAACT TCAGCATCCA 920AGTTTATGAA TCGTAGTTAA CGTATATTGC TGTTAATATA GTTTAGGAGT 970AAGAGTCTTG TTTTTTATTC AGATTGGGAA ATCCGTTCTA TTTTGTGAAT 1020TTGGGACATA ATAACAGCAG TGGAGTAAGT ATTTAGAAGT GTGAATTC 1068(2)SEQ ID NO.16的信息(i)序列特征:
(A)长度:2226bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-5基因(xi)序列描述:SEQ ID NO.16GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT TTTTAGCTGA 550GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 686CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 728GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 770TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 812AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 854CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 896TGG CTG ACT TGA 908TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCTGGT CACAAAGGCA 958GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1008CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1058AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1108CTCCTATGAT GGCCTGCTGG TTGATAATAA TCAGATCATG CCCAAGACGG 1158GCCTCCTGAT AATCGTCTTG GGCATGATTG CAATGGAGGG CAAATGCGTC 1208CCTGAGGAGA AAATCTGGGA GGAGCTGAGT GTGATGAAGG TGTATGTTGG 1258GAGGGAGCAC AGTGTCTGTG GGGAGCCCAG GAAGCTGCTC ACCCAAGATT 1308TGGTGCAGGA AAACTACCTG GAGTACCGGC AGGTGCCCAG CAGTGATCCC 1358ATATGCTATG AGTTACTGTG GGGTCCAAGG GCACTCGCTG CTTGAAAGTA 1408CTGGAGCACG TGGTCAGGGT CAATGCAAGA GTTCTCATTT CCTACCCATC 1458CCTGCGTGAA GCAGCTTTGA GAGAGGAGGA AGAGGGAGTC TGAGCATGAG 1508CTGCAGCCAG GGCCACTGCG AGGGGGGCTG GGCCAGTGCA CCTTCCAGGG 1558CTCCGTCCAG TAGTTTCCCC TGCCTTAATG TGACATGAGG CCCATTCTTC 1608TCTCTTTGAA GAGAGCAGTC AACATTCTTA GTAGTGGGTT TCTGTTCTAT 1658TGGATGACTT TGAGATTTGT CTTTGTTTCC TTTTGGAATT GTTCAAATGT 1708TTCTTTTAAT GGGTGGTTGA ATGAACTTCA GCATTCAAAT TTATGAATGA 1758CAGTAGTCAC ACATAGTGCT GTTTATATAG TTTAGGAGTA AGAGTCTTGT 1808TTTTTATTCA GATTGGGAAA TCCATTCCAT TTTGTGAATT GGGACATAGT 1858TACAGCAGTG GAATAAGTAT TCATTTAGAA ATGTGAATGA GCAGTAAAAC 1908TGATGACATA AAGAAATTAA AAGATATTTA ATTCTTGCTT ATACTCAGTC 1958TATTCGGTAA AATTTTTTTT AAAAAATGTG CATACCTGGA TTTCCTTGGC 2008TTCTTTGAGA ATGTAAGACA AATTAAATCT GAATAAATCA TTCTCCCTGT 2058TCACTGGCTC ATTTATTCTC TATGCACTGA GCATTTGCTC TGTGGAAGGC 2108CCTGGGTTAA TAGTGGAGAT GCTAAGGTAA GCCAGACTCA CCCCTACCCA 2158CAGGGTAGTA AAGTCTAGGA GCAGCAGTCA TATAATTAAG GTGGAGAGAT 2208GCCCTCTAAG ATGTAGAG 2226(2)SEQ ID NO.17的信息(i)序列特征:
(A)长度:2305bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-51基因(xi)序列描述:SEQ ID NO.17GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT TTTTAGCTGA 550GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 686GGC CTT GAC ACC CAA GAA GAG CCC TGG GCC TGG TGG GTG TGC 728AGG CTG CCA CTA CTG AGG AGC AGG AGG CTG TGT CCT CCT CCT 770CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 812GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 854TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 896AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 938CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 980TGG CTG ACT TGA 992TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCCGGT CACAAAGGCA 1042GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1092CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1142AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1192CTCCTATGAT GGCCTGGTGG TTTAATCAGA TCATGCCCAA GACGGGCCTC 1242CTGATAATCG TCTTGGGCAT GATTGCAATG GAGGGCAAAT GCGTCCCTGA 1292GGAGAAAATC TGGGAGGAGC TGGGTGTGAT GAAGGTGTAT GTTGGGAGGG 1342AGCACAGTGT CTGTGGGGAG CCCAGGAAGC TGCTCACCCA AGATTTGGTG 1392CAGGAAAACT ACCTGGAGTA CCGCAGGTGC CCAGCAGTGA TCCCATATGC 1442TATGAGTTAC TGTGGGGTCC AAGGGCACTC GCTGCTTGAA AGTACTGGAG 1492CACGTGGTCA GGGTCAATGC AAGAGTTCTC ATTTCCTACC CATCCCTGCA 1542TGAAGCAGCT TTGAGAGAGG AGGAAGAGGG AGTCTGAGCA TGAGCTGCAG 1592CCAGGGCCAC TGCGAGGGGG GCTGGGCCAG TGCACCTTCC AGGGCTCCGT 1642CCAGTAGTTT CCCCTGCCTT AATGTGACAT GAGGCCCATT CTTCTCTCTT 1692TGAAGAGAGC AGTCAACATT CTTAGTAGTG GGTTTCTGTT CTATTGGATG 1742ACTTTGAGAT TTGTCTTTGT TTCCTTTTGG AATTGTTCAA ATGTTCCTTT 1792TAATGGGTGG TTGAATGAAC TTCAGCATTC AAATTTATGA ATGACAGTAG 1842TCACACATAG TGCTGTTTAT ATAGTTTAGG AGTAAGAGTC TTGTTTTTTA 1892TTCAGATTGG GAAATCCATT CCATTTTGTG AATTGGGACA TAGTTACAGC 1942AGTGGAATAA GTATTCATTT AGAAATGTGA ATGAGCAGTA AAACTGATGA 1992GATAAAGAAA TTAAAAGATA TTTAATTCTT GCCTTATACT CAGTCTATTC 2042GGTAAAATTT TTTTTTAAAA ATGTGCATAC CTGGATTTCC TTGGCTTCTT 2092TGAGAATGTA AGACAAATTA AATCTGAATA AATCATTCTC CCTGTTCACT 2142GGCTCATTTA TTCTCTATGC ACTGAGCATT TGCTCTGTGG AAGGCCCTGG 2192GTTAATAGTG GAGATGCTAA GGTAAGCCAG ACTCACCCCT ACCCACAGGG 2242TAGTAAAGTC TAGGAGCAGC AGTCATATAA TTAAGGTGGA GAGATGCCCT 2292CTAAGATGTA GAG 2305(2)SEQ ID NO.18的信息(i)序列特征:
(A)长度:225bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:cDNA(ix)特征:
(A)名称/关键:MAGE-6基因(xi)序列描述:SEQ ID NO.18TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT TCC GAT TCC TTG 42CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA GTG GAC CCC ATC 84GGC CAC GTG TAC ATC TTT GCC ACC TGC CTG GGC CTC TCC TAC 126GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG CCC AGG ACA GGC 168TTC CTG ATA ATC ATC CTG GCC ATA ATC GCA AGA GAG GGC GAC 210TGT GCC CCT GAG GAG 225(2)SEQ ID NO.19的信息(i)序列特征:
(A)长度:1947bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-7基因(xi)序列描述:SEQ ID NO.19TGAATGGACA ACAAGGGCCC CACACTCCCC AGAACACAAG GGACTCCAGA 50GAGCCCAGCC TCACCTTCCC TACTGTCAGT CCTGCAGCCT CAGCCTCTGC 100TGGCCGGCTG TACCCTGAGG TGCCCTCTCA CTTCCTCCTT CAGGTTCTCA 150GCGGACAGGC CGGCCAGGAG GTCAGAAGCC CCAGGAGGCC CCAGAGGAGC 200ACCGAAGGAG AAGATCTGTA AGTAGGCCTT TGTTAGGGCC TCCAGGGCGT 250GGTTCACAAA TGAGGCCCCT CACAAGCTCC TTCTCTCCCC AGATCTGTGG 300GTTCCTCCCC ATCGCCCAGC TGCTGCCCGC ACTCCAGCCT GCTGCCCTGA 350CCAGAGTCAT CATGTCTTCT GAGCAGAGGA GTCAGCACTG CAAGCCTGAG 400GATGCCTTGA GGCCCAAGGA CAGGAGGCTC TGGGCCTGGT GGGTGCGCAG 450GCTCCCGCCA CCGAGGAGCA CGAGGCTGCC TCCTCCTTCA CTCTGATTGA 500AGGCACCCTG GAGGAGGTGC CTGCTGCTGG GTCCCCCAGT CCTCCCCTGA 550GTCTCAGGGT TCCTCCTTTT CCCTGACCAT CAGCAACAAC ACTCTATGGA 600GCCAATCCAG TGAGGGCACC AGCAGCCGGG AAGAGGAGGG GCCAACCACC 650TAGACACACC CCGCTCACCT GGCGTCCTTG TTCCA 685ATG GGA AGG TGG CTG AGT TGG TTC GCT TCC TGC TGC ACA AGT 727ATC GAG TCA AGG AGC TGG TCA CAA AGG CAG AAA TGC TGG ACA 769GTG TCA TCA AAA ATT ACA AGC ACT AGT TTC CTT GTG ATC TAT 811GGC AAA GCC TCA GAG TGC ATG CAG GTG ATG TTT GGC ATT GAC 853ATG AAG GAA GTG GAC CCC GCG GCC ACT CCT ACG TCC TTG TCA 895CCT GCT TGG GCC TCT CCT ACA ATG GCC TGC TGG GTG ATG ATC 937AGA GCA TGC CCG AGA CCG GCC TTC TGA 964TTATGGTCTT GACCATGATC TTAATGGAGG GCCACTGTGC CCCTGAGGAG 1014GCAATCTGGG AAGCGTTGAG TGTAATGGTG TATGATGGGA TGGAGCAGTT 1064TCTTTGGGCA GCTGAGGAAG CTGCTCACCC AAGATTGGGT GCAGGAAAAC 1114TACCTGCAAT ACCGCCAGGT GCCCAGCAGT GATCCCCCGT GCTACCAGTT 1164CCTGTGGGGT CCAAGGGCCC TCATTGAAAC CAGCTATGTG AAAGTCCTGG 1214AGTATGCAGC CAGGGTCAGT ACTAAAGAGA GCATTTCCTA CCCATCCCTG 1264 CATGAAGAGG CTTTGGGAGA GGAGGAAGAG GGAGTCTGAG CAGAAGTTGC 1314AGCCAGGGCC AGTGGGGCAG ATTGGGGGAG GGCCTGGGCA GTGCACGTTC 1364CACACATCCA CCACCTTCCC TGTCCTGTTA CATGAGGCCC ATTCTTCACT 1414CTGTGTTTGA AGAGAGCAGT CAATGTTCTC AGTAGCGGGG AGTGTGTTGG 1464GTGTGAGGGA ATACAAGGTG GACCATCTCT CAGTTCCTGT TCTCTTGGGC 1514GATTTGGAGG TTTATCTTTG TTTCCTTTTG CAGTCGTTCA AATGTTCCTT 1564TTAATGGATG GTGTAATGAA CTTCAACATT CATTTCATGT ATGACAGTAG 1614GCAGACTTAC TGTTTTTTAT ATAGTTAAAA GTAAGTGCAT TGTTTTTTAT 1664TTATGTAAGA AAATCTATGT TATTTCTTGA ATTGGGACAA CATAACATAG 1714CAGAGGATTA AGTACCTTTT ATAATGTGAA AGAACAAAGC GGTAAAATGG 1764GTGAGATAAA GAAATAAAGA AATTAAATTG GCTGGGCACG GTGGCTCACG 1814CCTGTAATCC CAGCACTTTA GGAGGCAGAG GCACGGGGAT CACGAGGTCA 1864GGAGATCGAG ACCATTCTGG CTAACACAGT GAAACACCAT CTCTATTAAA 1914AATACAAAAC TTAGCCGGGC GTGGTGGCGG GTG 1947(2)SEQ ID NO.20的信息(i)序列特征:
(A)长度:1810bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-8基因(xi)序列描述:SEQ ID NO.20GAGCTCCAGG AACCAGGCTG TGAGGTCTTG GTCTGAGGCA GTATCTTCAA 50TCACAGAGCA TAAGAGGCCC AGGCAGTAGT AGCAGTCAAG CTGAGGTGGT 100GTTTCCCCTG TATGTATACC AGAGGCCCCT CTGGCATCAG AACAGCAGGA 150ACCCCACAGT TCCTGGCCCT ACCAGCCCTT TTGTCAGTCC TGGAGCCTTG 200GCCTTTGCCA GGAGGCTGCA CCCTGAGATG CCCTCTCAAT TTCTCCTTCA 250GGTTCGCAGA GAACAGGCCA GCCAGGAGGT CAGGAGGCCC CAGAGAAGCA 300CTGAAGAAGA CCTGTAAGTA GACCTTTGTT AGGGCATCCA GGGTGTAGTA 350CCCAGCTGAG GCCTCTCACA CGCTTCCTCT CTCCCCAGGC CTGTGGGTCT 400CAATTGCCCA GCTCCGGCCC ACACTCTCCT GCTGCCCTGA CCTGAGTCAT 450C 451ATG CTT CTT GGG CAG AAG AGT CAG CGC TAC AAG GCT GAG GAA 493GGC CTT CAG GCC CAA GGA GAG GCA CCA GGG CTT ATG GAT GTG 535CAG ATT CCC ACA GCT GAG GAG CAG AAG GCT GCA TCC TCC TCC 577TCT ACT CTG ATC ATG GGA ACC CTT GAG GAG GTG ACT GAT TCT 619GGG TCA CCA AGT CCT CCC CAG AGT CCT GAG GGT GCC TCC TCT 661TCC CTG ACT GTC ACC GAC AGC ACT CTG TGG AGC CAA TCC GAT 703GAG GGT TCC AGC AGC AAT GAA GAG GAG GGG CCA AGC ACC TCC 745CCG GAC CCA GCT CAC CTG GAG TCC CTG TTC CGG GAA GCA CTT 787GAT GAG AAA GTG GCT GAG TTA GTT CGT TTC CTG CTC CGC AAA 829TAT CAA ATT AAG GAG CCG GTC ACA AAG GCA GAA ATG CTT GAG 871AGT GTC ATC AAA AAT TAC AAG AAC CAC TTT CCT GAT ATC TTC 913AGC AAA GCC TCT GAG TGC ATG CAG GTG ATC TTT GGC ATT GAT 955GTG AAG GAA GTG GAC CCT GCC GGC CAC TCC TAC ATC CTT GTC 997ACC TGC CTG GGC CTC TCC TAT GAT GGC CTG CTG GGT GAT GAT 1039CAG AGT ACG CCC AAG ACC GGC CTC CTG ATA ATC GTC CTG GGC 1081ATG ATC TTA ATG GAG GGC AGC CGC GCC CCG GAG GAG GCA ATC 1123TGG GAA GCA TTG AGT GTG ATG GGG GCT GTA TGA 1156TGGGAGGGAG CACAGTGTCT ATTGGAAGCT CAGGAAGCTG CTCACCCAAG 1206AGTGGGTGCA GGAGAACTAC CTGGAGTACC GCCAGGCGCC CGGCAGTGAT 1256CCTGTGCGCT ACGAGTTCCT GTGGGGTCCA AGGGCCCTTG CTGAAACCAG 1306CTATGTGAAA GTCCTGGAGC ATGTGGTCAG GGTCAATGCA AGAGTTCGCA 1356TTTCCTACCC ATCCCTGCAT GAAGAGGCTT TGGGAGAGGA GAAAGGAGTT 1406TGAGCAGGAG TTGCAGCTAG GGCCAGTGGG GCAGGTTGTG GGAGGGCCTG 1456GGCCAGTGCA CGTTCCAGGG CCACATCCAC CACTTTCCCT GCTCTGTTAC 1506ATGAGGCCCA TTCTTCACTC TGTGTTTGAA GAGAGCAGTC ACAGTTCTCA 1556GTAGTGGGGA GCATGTTGGG TGTGAGGGAA CACAGTGTGG ACCATCTCTC 1606AGTTCCTGTT CTATTGGGCG ATTTGGAGGT TTATCTTTGT TTCCTTTTGG 1656AATTGTTCCA ATGTTCCTTC TAATGGATGG TGTAATGAAC TTCAACATTC 1706ATTTTATGTA TGACAGTAGA CAGACTTACT GCTTTTTATA TAGTTTAGGA 1756GTAAGAGTCT TGCTTTTCAT TTATACTGGG AAACCCATGT TATTTCTTGA 1806ATTC 1810(2)SEQ ID NO.21的信息(i)序列特征:
(A)长度:1412bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-9基因(xi)序列描述:SEQ ID NO.21TCTGAGACAG TGTCCTCAGG TCGCAGAGCA GAGGAGACCC AGGCAGTGTC 50AGCAGTGAAG GTGAAGTGTT CACCCTGAAT GTGCACCAAG GGCCCCACCT 100GCCCCAGCAC ACATGGGACC CCATAGCACC TGGCCCCATT CCCCCTACTG 150TCACTCATAG AGCCTTGATC TCTGCAGGCT AGCTGCACGC TGAGTAGCCC 200TCTCACTTCC TCCCTCAGGT TCTCGGGACA GGCTAACCAG GAGGACAGGA 250GCCCCAAGAG GCCCCAGAGC AGCACTGACG AAGACCTGTA AGTCAGCCTT 300TGTTAGAACC TCCAAGGTTC GGTTCTCAGC TGAAGTCTCT CACACACTCC 350CTCTCTCCCC AGGCCTGTGG GTCTCCATCG CCCAGCTCCT GCCCACGCTC 400CTGACTGCTG CCCTGACCAG AGTCATC 427ATG TCT CTC GAG CAG AGG AGT CCG CAC TGC AAG CCT GAT GAA 469GAC CTT GAA GCC CAA GGA GAG GAC TTG GGC CTG ATG GGT GCA 511CAG GAA CCC ACA GGC GAG GAG GAG GAG ACT ACC TCC TCC TCT 553GAC AGC AAG GAG GAG GAG GTG TCT GCT GCT GGG TCA TCA AGT 595CCT CCC CAG AGT CCT CAG GGA GGC GCT TCC TCC TCC ATT TCC 637GTC TAC TAC ACT TTA TGG AGC CAA TTC GAT GAG GGC TCC AGC 679AGT CAA GAA GAG GAA GAG CCA AGC TCC TCG GTC GAC CCA GCT 721CAG CTG GAG TTC ATG TTC CAA GAA GCA CTG AAA TTG AAG GTG 763GCT GAG TTG GTT CAT TTC CTG CTC CAC AAA TAT CGA GTC AAG 805GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGC GTC ATC AAA 847AAT TAC AAG CGC TAC TTT CCT GTG ATC TTC GGC AAA GCC TCC 889GAG TTC ATG CAG GTG ATC TTT GGC ACT GAT GTG AAG GAG GTG 931GAC CCC GCC GGC CAC TCC TAC ATC CTT GTC ACT GCT CTT GGC 973CTC TCG TGC GAT AGC ATG CTG GGT GAT GGT CAT AGC ATG CCC 1015AAG GCC GCC CTC CTG ATC ATT GTC CTG GGT GTG ATC CTA ACC 1057AAA GAC AAC TGC GCC CCT GAA GAG GTT ATC TGG GAA GCG TTG 1099AGT GTG ATG GGG GTG TAT GTT GGG AAG GAG CAC ATG TTC TAC 1141GGG GAG CCC AGG AAG CTG CTC ACC CAA GAT TGG GTG CAG GAA 1183AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT GCG 1225CAC TAC GAG TTC CTG TGG GGT TCC AAG GCC CAC GCT GAA ACC 1267AGC TAT GAG AAG GTC ATA AAT TAT TTG GTC ATG CTC AAT GCA 1309AGA GAG CCC ATC TGC TAC CCA TCC CTT TAT GAA GAG GTT TTG 1351GGA GAG GAG CAA GAG GGA GTC TGA 1375GCACCAGCCG CAGCCGGGGC CAAAGTTTGT GGGGTCA 1412(2)SEQ ID NO.22的信息(i)序列特征:
(A)长度:920bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-10基因(xi)序列描述:SEQ ID NO.22ACCTGCTCCA GGACAAAGTG GACCCCACTG CATCAGCTCC ACCTACCCTA 50CTGTCAGTCC TGGAGCCTTG GCCTCTGCCG GCTGCATCCT GAGGAGCCAT 100CTCTCACTTC CTTCTTCAGG TTCTCAGGGG ACAGGGAGAG CAAGAGGTCA 150AGAGCTGTGG GACACCACAG AGCAGCACTG AAGGAGAAGA CCTGTAAGTT 200GGCCTTTGTT AGAACCTCCA GGGTGTGGTT CTCAGCTGTG GCCACTTACA 250CCCTCCCTCT CTCCCCAGGC CTGTGGGTCC CCATCGCCCA AGTCCTGCCC 300ACACTCCCAC CTGCTACCCT GATCAGAGTC ATC 333ATG CCT CGA GCT CCA AAG CGT CAG CGC TGC ATG CCT GAA GAA 375GAT CTT CAA TCC CAA AGT GAG ACA CAG GGC CTC GAG GGT GCA 417CAG GCT CCC CTG GCT GTG GAG GAG GAT GCT TCA TCA TCC ACT 459TCC ACC AGC TCC TCT TTT CCA TCC TCT TTT CCC TCC TCC TCC 501TCT TCC TCC TCC TCC TCC TGC TAT CCT CTA ATA CCA AGC ACC 543CCA GAG GAG GTT TCT GCT GAT GAT GAG ACA CCA AAT CCT CCC 585CAG AGT GCT CAG ATA GCC TGC TCC TCC CCC TCG GTC GTT GCT 627TCC CTT CCA TTA GAT CAA TCT GAT GAG GGC TCC AGC AGC CAA 669AAG GAG GAG AGT CCA AGC ACC CTA CAG GTC CTG CCA GAC AGT 711GAG TCT TTA CCC AGA AGT GAG ATA GAT GAA AAG GTG ACT GAT 753TTG GTG CAG TTT CTG CTC TTC AAG TAT CAA ATG AAG GAG CCG 795ATC ACA AAG GCA GAA ATA CTG GAG AGT GTC ATA AAA AAT TAT 837GAA GAC CAC TTC CCT TTG TTG TTT AGT GAA GCC TCC GAG TGC 879ATG CTG CTG GTC TTT GGC ATT GAT GTA AAG GAA GTG GAT CC 920(2)SEQ ID NO.23的信息(i)序列特征:
(A)长度:1107bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:MAGE-11基因(xi)序列描述: SEQ ID NO.23AGAGAACAGG CCAACCTGGA GGACAGGAGT CCCAGGAGAA CCCAGAGGAT 50CACTGGAGGA GAACAAGTGT AAGTAGGCCT TTGTTAGATT CTCCATGGTT 100CATATCTCAT CTGAGTCTGT TCTCACGCTC CCTCTCTCCC CAGGCTGTGG 150GGCCCCATCA CCCAGATATT TCCCACAGTT CGGCCTGCTG ACCTAACCAG 200AGTCATCATG CCTCTTGAGC AAAGAAGTCA GCACTGCAAG CCTGAGGAAG 250CCTTCAGGCC CAAGAAGAAG ACCTGGGCCT GGTGGGTGCA CAGGCTCTCC 300AAGCTGAGGA GCAGGAGGCT GCCTTCTTCT CCTCTACTCT GAATGTGGGC 350ACTCTAGAGG AGTTGCCTGC TGCTGAGTCA CCAAGTCCTC CCCAGAGTCC 400TCAGGAAGAG TCCTTCTCTC CCACTGCCAT GGATGCCATC TTTGGGAGCC 450TATCTGATGA GGGCTCTGGC AGCCAAGAAA AGGAGGGGCC AAGTACCTCG 500CCTGACCTGA TAGACCCTGA GTCCTTTTCC CAAGATATAC TACATGACAA 550GATAATTGAT TTGGTTCATT TATTCTCCGC AAGTATCGAG TCAAGGGGCT 600GATCACAAAG GCAGAA 616ATG CTG GGG AGT GTC ATC AAA AAT TAT GAG GAC TAC TTT CCT 658GAG ATA TTT AGG GAA GCC TCT GTA TGC ATG CAA CTG CTC TTT 700GGC ATT GAT GTG AAG GAA GTG GAC CCC ACT AGC CAC TCC TAT 742GTC CTT GTC ACC TCC CTC AAC CTC TCT TAT GAT GGC ATA CAG 784TGT AAT GAG CAG AGC ATG CCC AAG TCT GGC CTC CTG ATA ATA 826GTC CTG GGT GTA ATC TTC ATG GAG GGG AAC TGC ATC CCT GAA 868GAG GTT ATG TGG GAA GTC CTG AGC ATT ATG GGG GTG TAT GCT 910GGA AGG GAG CAC TTC CTC TTT GGG GAG CCC AAG AGG CTC CTT 952ACC CAA AAT TGG GTG CAG GAA AAG TAC CTG GTG TAC CGG CAG 994GTG CCC GGC ACT GAT CCT GCA TGC TAT GAG TTC CTG TGG GGT 1036CCA AGG GCC CAC GCT GAG ACC AGC AAG ATG AAA GTT CTT GAG 1078TAC ATA GCC AAT GCC AAT GGG AGG GAT CC 1107(2)SEQ ID NO.24的信息(i)序列特征:
(A)长度:2150bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:smage-I(xi)序列描述:SEQ ID NO.24TCTGTCTGCA TATGCCTCCA CTTGTGTGTA GCAGTCTCAA ATGGATCTCT 50CTCTACAGAC CTCTGTCTGT GTCTGGCACC CTAAGTGGCT TTGCATGGGC 100ACAGGTTTCT GCCCCTGCAT GGAGCTTAAA TAGATCTTTC TCCACAGGCC 150TATACCCCTG CATTGTAAGT TTAAGTGGCT TTATGTGGAT ACAGGTCTCT 200GCCCTTGTAT GCAGGCCTAA GTTTTTCTGT CTGCTTAACC CCTCCAAGTG 250AAGCTAGTGA AAGATCTAAC CCACTTTTGG AAGTCTGAAA CTAGACTTTT 300ATGCAGTGGC CTAACAAGTT TTAATTTCTT CCACAGGGTT TGCAGAAAAG 350AGCTTGATCC ACGAGTTCAG AAGTCCTGGT ATGTTCCTAG AAAG 394ATG TTC TCC TGG AAA GCT TCA AAA GCC AGG TCT CCA TTA AGT 436CCA AGG TAT TCT CTA CCT GGT AGT ACA GAG GTA CTT ACA GGT 478TGT CAT TCT TAT CCT TCC AGA TTC CTG TCT GCC AGC TCT TTT 520ACT TCA GCC CTG AGC ACA GTC AAC ATG CCT AGG GGT CAA AAG 562AGT AAG ACC CGC TCC CGT GCA AAA CGA CAG CAG TCA CGC AGG 604GAG GTT CCA GTA GTT CAG CCC ACT GCA GAG GAA GCA GGG TCT 646TCT CCT GTT GAC CAG AGT GCT GGG TCC AGC TTC CCT GGT GGT 688TCT GCT CCT CAG GGT GTG AAA ACC CCT GGA TCT TTT GGT GCA 730GGT GTA TCC TGC ACA GGC TCT GGT ATA GGT GGT AGA AAT GCT 772GCT GTC CTG CCT GAT ACA AAA AGT TCA GAT GGC ACC CAG GCA 814GGG ACT TCC ATT CAG CAC ACA CTG AAA GAT CCT ATC ATG AGG 856AAG GCT AGT GTG CTG ATA GAA TTC CTG CTA GAT AAA TTT AAG 898ATG AAA GAA GCA GTT ACA AGG AGT GAA ATG CTG GCA GTA GTT 940AAC AAG AAG TAT AAG GAG CAA TTC CCT GAG ATC CTC AGG AGA 982ACT TCT GCA CGC CTA GAA TTA GTC TTT GGT CTT GAG TTG AAG 1024GAA ATT GAT CCC AGC ACT CAT TCC TAT TTG CTG GTA GGC AAA 1066CTG GGT CTT TCC ACT GAG GGA AGT TTG AGT AGT AAC TGG GGG 1108TTG CCT AGG ACA GGT CTC CTA ATG TCT GTC CTA GGT GTG ATC 1150TTC ATG AAG GGT AAC CGT GCC ACT GAG CAA GAG GTC TGG CAA 1192TTT CTG CAT GGA GTG GGG GTA TAT GCT GGG AAG AAG CAC TTG 1234ATC TTT GGC GAG CCT GAG GAG TTT ATA AGA GAT GTA GTG CGG 1276GAA AAT TAC CTG GAG TAC CGC CAG GTA CCT GGC AGT GAT CCC 1318CCA AGC TAT GAG TTC CTG TGG GGA CCC AGA GCC CAT GCT GAA 1360ACA ACC AAG ATG AAA GTC CTG GAA GTT TTA GCT AAA GTC AAT 1402GGC ACA GTC CCT AGT GCC TTC CCT AAT CTC TAC CAG TTG GCT 1444CTT AGA GAT CAG GCA GGA GGG GTG CCA AGA AGG AGA GTT CAA 1486GGC AAG GGT GTT CAT TCC AAG GCC CCA TCC CAA AAG TCC TCT 1528AAC ATG TAG 1537TTGAGTCTGT TCTGTTGTGT TTGAAAAACA GTCAGGCTCC TAATCAGTAG 1587AGAGTTCATA GCCTACCAGA ACCAACATGC ATCCATTCTT GGCCTGTTAT 1637ACATTAGTAG AATGGAGGCT ATTTTTGTTA CTTTTCAAAT GTTTGTTTAA 1687CTAAACAGTG CTTTTTGCCA TGCTTCTTGT TAACTGCATA AAGAGGTAAC 1737TGTCACTTGT CAGATTAGGA CTTGTTTTGT TATTTGCAAC AAACTGGAAA 1787ACATTATTTT GTTTTTACTA AAACATTGTG TAACATTGCA TTGGAGAAGG 1837GATTGTCATG GCAATGTGAT ATCATACAGT GGTGAAACAA CAGTGAAGTG 1887GGAAAGTTTA TATTGTTAAT TTTGAAAATT TTATGAGTGT GATTGCTGTA 1937TACTTTTTTC TTTTTTGTAT AATGCTAAGT GAAATAAAGT TGGATTTGAT 1987GACTTTACTC AAATTCATTA GAAAGTAAAT CGTAAAACTC TATTACTTTA 2037TTATTTTCTT CAATTATGAA TTAAGCATTG GTTATCTGGA AGTTTCTCCA 2087GTAGCACAGG ATCTAGTATG AAATGTATCT AGTATAGGCA CTGACAGTGA 2137GTTATCAGAG TCT 2150(2)SEQ ID NO.25的信息(i)序列特征:
(A)长度:2099bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:基因组DNA(ix)特征:
(A)名称/关键:smage-II(xi)序列描述:SEQ ID NO.25ACCTTATTGG GTCTGTCTGC ATATGCCTCC ACTTGTGTGT AGCAGTCTCA 50AATGGATCTC TCTCTACAGA CCTCTGTCTG TGTCTGGCAC CCTAAGTGGC 100TTTGCATGGG CACAGGTTTC TGCCCCTGCA TGGAGCTTAA ATAGATCTTT 150CTCCACAGGC CTATACCCCT GCATTGTAAG TTTAAGTGGC TTTATGTGGA 200TACAGGTCTC TGCCCTTGTA TGCAGGCCTA AGTTTTTCTG TCTGCTTAGC 250CCCTCCAAGT GAAGCTAGTG AAAGATCTAA CCCACTTTTG GAAGTCTGAA 300ACTAGACTTT TATGCAGTGG CCTAACAAGT TTTAATTTCT TCCACAGGGT 350TTGCAGAAAA GAGCTTGATC CACGAGTTCG GAAGTCCTGG TATGTTCCTA 400GAAAGATGTT CTCCTGGAAA GCTTCAAAAG CCAGGTCTCC ATTAAGTCCA 450AGGTATTCTC TACCTGGTAG TACAGAGGTA CTTACAGGTT GTCATTCTTA 500TCTTTCCAGA TTCCTGTCTG CCAGCTCTTT TACTTCAGCC CTGAGCACAG 550TCAACATGCC TAGGGGTCAA AAGAGTAAGA CCCGCTCCCG TGCAAAACGA 600CAGCAGTCAC GCAGGGAGGT TCCAGTAGTT CAGCCCACTG CAGAGGAAGC 650AGGGTCTTCT CCTGTTGACC AGAGTGCTGG GTCCAGCTTC CCTGGTGGTT 700CTGCTCCTCA GGGTGTGAAA ACCCCTGGAT CTTTTGGTGC AGGTGTATCC 750TGCACAGGCT CTGGTATAGG TGGTAGAAAT GCTGCTGTCC TGCCTGATAC 800AAAAAGTTCA GATGGCACCC AGGCAGGGAC TTCCATTCAG CACACACTGA 850AAGATCCTAT CATGAGGAAG GCTAGTGTGC TGATAGAATT CCTGCTAGAT 900AAGTTTAAGA TGAAAGAAGC AGTTACAAGG AGTGAAATGC TGGCAGTAGT 950TAACAAGAAG TATAAGGAGC AATTCCCTGA GATCCTCAGG AGAACTTCTG 1000CACGCCTAGA ATTAGTCTTT GGTCTTGAGT TGAAGGAAAT TGATCCCAGC 1050ACTCATTCCT ATTTGCTGGT AGGCAAACTG GGTCTTTCCA CTGAGGGAAG 1100TTTGAGTAGT AACTGGGGGT TGCCTAGGAC AGGTCTCCTA ATGTCTGTCC 1150TAGGTGTGAT CTTCATGAAG GGTAACCGTG CCACTGAGCA AGAGGTCTGG 1200CAATTTCTGC ATGGAGTGGG GGTATATGCT GGGAAGAAGC ACTTGATCTT 1250TGGCGAGCCT GAGGAGTTTA TAAGAGATGT AGTGCGGGAA AATTACCTGG 1300AGTACCGCCA GGTACCTGGC AGTGATCCCC CAAGCTATGA GTTCCTGTGG 1350GGACCCAGAG CCCATGCTGA AACAACCAAG ATGAAAGTCC TGGAAGTTTT 1400AGCTAAAGTC AATGGCACAG TCCCTAGTGC CTTCCCTAAT CTCTACCAGT 1450TGGCTCTTAG AGATCAGGCA GGAGGGGTGC CAAGAAGGAG AGTTCAAGGC 1500AAGGGTGTTC ATTCCAAGGC CCCATCCCAA AAGTCCTCTA ACATGTAGTT 1550GAGTCTGTTC TGTTGTGTTT GAAAAACAGT CAGGCTCCTA ATCAGTAGAG 1600AGTTCATAGC CTACCAGAAC CAACATGCAT CCATTCTTGG CCTGTTATAC 1650ATTAGTAGAA TGGAGGCTAT TTTTGTTACT TTTCAAATGT TTGTTTAACT 1700AAACAGTGCT TTTTGCCATG CTTCTTGTTA ACTGCATAAA GAGGTAACTG 1750TCACTTGTCA GATTAGGACT TGTTTTGTTA TTTGCAACAA ACTGGAAAAC 1800ATTATTTTGT TTTTACTAAA ACATTGTGTA ACATTGCATT GGAGAAGGGA 1850TTGTCATGGC AATGTGATAT CATACAGTGG TGAAACAACA GTGAAGTGGG 1900AAAGTTTATA TTGTTAGTTT TGAAAATTTT ATGAGTGTGA TTGCTGTATA 1950CTTTTTTCTT TTTTGTATAA TGCTAAGTGA AATAAAGTTG GATTTGATGA 2000CTTTACTCAA ATTCATTAGA AAGTAAATCA TAAAACTCTA TTACTTTATT 2050ATTTTCTTCA ATTATTAATT AAGCATTGGT TATCTGGAAG TTTCTCCAG 2099(2)SEQ ID NO.26的信息
(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性
(ii)分子类型:蛋白质
(xi)序列描述:SEQ ID NO.26
Glu Ala Asp Pro Thr Gly His Ser Tyr
5(2)SEQ ID NO.27的信息
(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性
(ii)分子类型:蛋白质
(xi)序列描述:SEQ ID NO.27 Glu Val Val Pro Ile Ser His Leu Tyr
5(2)SEQ ID NO.28的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.28Glu Val Val Arg Ile Gly His Leu Tyr
5(2)SEQ ID NO.29的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.29Glu Val Asp Pro Ile Gly His Leu Tyr
5(2)SEQ ID NO.30的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.30Gly Val Asp Pro Ala Ser Asn Thr Tyr
5(2)SEQ ID NO.31的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性
(ii)分子类型:蛋白质
(xi)序列描述:SEQ ID NO.31
Glu Val Asp Pro Thr Ser Asn Thr Tyr
5(2)SEQ ID NO.32的信息
(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.32Glu Ala Asp Pro Thr Ser Asn Thr Tyr
5(2)SEQ ID NO.33的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.33Glu Ala Asp Pro Thr Ser Asn Thr Tyr
5(2)SEQ ID NO.34的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.34Glu Val Asp Pro Ile Gly His Val Tyr
5(2)SEQ ID NO.35的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.35Tyr Met Asn Gly Thr Met Ser Gln Val
5(2)SEQ ID NO.36的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.36Met Leu Leu Ala Val Leu Tyr Cys Leu Leu
5 10(2)SEQ ID NO.37的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.37Met Leu Leu Ala Val Leu Tyr Cys Leu
5(2)SEQ ID NO.38的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.38Leu Leu Ala Val Leu Tyr Cys Leu Leu
5(2)SEQ ID NO.39的信息(i)序列特征:
(A)长度:13个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.39Ser Glu Ile Trp Arg Asp Ile Asp Phe Ala His Glu Ala
5 10(2)SEQ ID NO.40的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.40Ser Glu Ile Trp Arg Asp Ile Asp Phe Ala
5 10(2)SEQ ID NO.41的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.41Ser Glu Ile Trp Arg Asp Ile Asp Phe
5(2)SEQ ID NO.42的信息(i)序列特征:
(A)长度:16个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.42Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gln Asp Leu
5 10 15(2)SEQ ID NO.43的信息(i)序列特征:
(A)长度:12个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.43Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu
5 10(2)SEQ ID NO.44的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.44Ser Ala Tyr Gly Glu Pro Arg Lys Leu
5(2)SEQ ID NO.45的信息(i)序列特征:
(A)长度:1032bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.45CGCCAATTTA GGGTCTCCGG TATCTCCCGC TGAGCTGCTC TGTTCCCGGC TTAGAGGACC 60AGGAGAAGGG GGAGCTGGAG GCTGGAGCCT GTAACACCGT GGCTCGTCTC ACTCTGGATG 120GTGGTGGCAA CAGAGATGGC AGCGCAGCTG GAGTGTTAGG AGGGCGGCCT GAGCGGTAGG 180AGTGGGGCTG GAGCAGTAAG ATGGCGGCCA GAGCGGTTTT TCTGGCATTG TCTGCCCAGC 240TGCTCCAAGC CAGGCTGATG AAGGAGGAGT CCCCTGTGGT GAGCTGGAGG TTGGAGCCTG 300AAGACGGCAC AGCTCTGTGC TTCATCTTCT GAGGTTGTGG CAGCCACGGT GATGGAGACG 360GCAGCTCAAC AGGAGCAATA GGAGGAGATG GAGTTTCACT GTGTCAGCCA GGATGGTCTC 420GATCTCCTGA CCTCGTGATC CGCCCGCCTT GGCCTTCCAA AGTGCCGAGA TTACAGCGAT 480GTGCATTTTG TAAGCACTTT GGAGCCACTA TCAAATGCTG TGAAGAGAAA TGTACCCAGA 540TGTATCATTA TCCTTGTGCT GCAGGAGCCG GCTCCTTTCA GGATTTCAGT CACATCTTCC 600TGCTTTGTCC AGAACACATT GACCAAGCTC CTGAAAGATG TAAGTTTACT ACGCATAGAC 660TTTTAAACTT CAACCAATGT ATTTACTGAA AATAACAAAT GTTGTAAATT CCCTGAGTGT 720TATTCTACTT GTATTAAAAG GTAATAATAC ATAATCATTA AAATCTGAGG GATCATTGCC 780AGAGATTGTT GGGGAGGGAA ATGTTATCAA CGGTTTCATT GAAATTAAAT GTTATCAACG 840GTTTCATTGA AATTAAATCC AAAAAGTTAT TTCCTCAGAA AAATCAAATA AAGTTTGCAT 900GTTTTTTATT CTTAAAACAT TTTAAAAACC ACTGTAGAAT GATGTAAATA GGGACTGTGC 960AGTATTTCTG ACATATACTA TAAAATTATT AAAAAGTCAA TCAGTATTCA ACATCTTTTA 1020CACTAAAAAG CC 1032(2)SEQ ID NO.46的信息(i)序列特征:
(A)长度:22个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.46Met Ala Ala Arg Ala Val Phe Leu Ala Leu Ser Ala Gln Leu Leu Gln
5 10 15Ala Arg Leu Met Lys Glu
20(2)SEQ ID NO.47的信息(i)序列特征:
(A)长度:16个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.47Met Ala Ala Arg Ala Val Phe Leu Ala Leu Ser Ala Gln Leu Leu Gln
5 10 15(2)SEQ ID NO.48的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.48
Ala Ala Arg Ala Val Phe Leu Ala Leu
5(2)SEQ ID NO.49的信息(i)序列特征:
(A)长度:354bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.49ATG CGA AGA GAA GAT GCT CAC TTC ATC TAT GGT TAC CCC AAG AAG GGG 48Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly
5 10 15GAC GGC CAC TCT TAC ACC ACG GCT GAA GAG GCC GCT GGG ATC GGC ATC 96His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile
20 25 30CTG ACA GTG ATC CTG GGA GTC TTA CTG CTC ATC GGC TGT TGG TAT TGT 144Leu Thr Val Ile Leu Gly Val Leu Leu leu Ile Gly Cys Trp Tyr Cys
35 40 45AGA AGA CGA AAT GGA TAC AGA GCC TTG ATG GAT AAA AGT CTT CAT GTT 192Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val
50 55 60GGC ACT CAA TGT GCC TTA ACA AGA AGA TGC CCA CAA GAA GGG TTT GAT 240Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp65 70 75 80CAT CGG GAC AGC AAA GTG TCT CTT CAA GAG AAA AAC TGT GAA CCT GTG 288His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val
85 90 95GTT CCC AAT GCT CCA CCT GCT TAT GAG AAA CTC TCT GCA GAA CAG TCA 336Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser
100 105 110CCA CCA CCT TAT TCA CCT 354Pro Pro Pro Tyr Ser Pro
115(2)SEQ ID NO.50的信息(i)序列特征:
(A)长度:676bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.50TCTTCATACA CGCGGCCAGC CAGCAGACAG AGGACTCTCA TTAAGGAAGG TGTCCTGTGC 60CCTGACCCTA CAAGATGCCA AGAGAAGATG CTCACTTCAT CTATGGTTAC CCCAAGAAGG 120GGCACGGCCA CTCTTACACC ACGGCTGAAC AGGCCGCTGG GATCGGCATC CTGACAGTGA 180TCCTGGGAGT CTTACTGCTC ATCGGCTGTT GGTATTGTAG AAGACGAAAT GGATACAGAG 240CCTTGATGGA TAAAAGTCTT CATGTTGGCA CTCAATGTGC CTTAACAAGA AGATGCCCAC 300AAGAAGGGTT TGATCATCGG GACAGCAAAG TGTCTCTTCA AGAGAAAAAC TGTGAACCTG 360TGGTTCCCAA TGCTGCAGGT GCTTATGAGA AACTCTCTGC AGAACAGTCA GGACCACCTT 420ATTCACCTTA AGAGCCAGCG AGACACCTGA GACATGGCTG AAATTATTTC TCTCACACTT 480TTGCTTGAAT TTAATACAGA CATCTAATGT TCTCCTTTGG AATCCTGTAG GAAAAATGCA 540AGCCATCTCT AATAATAAGT CAGTGTTAAA ATTTTAGTAG GTCCGCTAGC AGTACTAATC 600ATGTGAGGAA ATGATGAGAA ATATTAAATT GGGAAAACTC CATCAATAAA TGTTGCAAAT 660GCATAGTAAA AAAAAA(2)SEQ ID NO.51的信息(i)序列特征:
(A)长度:13585bp
(B)类型:核酸
(C)链性:双链
(D)拓朴结构:线性(ix)特征:
(D)其它信息:在9421-9456位置处,“Ns”是指4.7-5.3kb的未
测序部分(xi)序列描述:SEQ ID NO.51CCGTCAGAAA TCTAAACCCG TGACTATCAT GGGACTCAAA ACCAGCCCAA AAAATAAGTC 60AAAACGATTA AGAGCCAGAG AAGCAGTCTT CATACACGCG GCCAGCCAGC AGACAGAGGA 120CTCTCATTAA GGAAGGTAAG AGCGTTGCCT TCTCGCCATA ATCATAGTCC TCTTCTCCCA 180GAATAGGATT TGGGAAATTC TGGCTAAGTC CTCTGCCTAC CCTCATTGCC CCGCTGATGT 240GTGACATCAA CAGAATTTCT CCGCAACGTT TGTCAGTCTC CAACCTCAGA GGGCTCACAA 300AGCCTCCTCC TGAATCCTCT CTCAGTCCTC CAACACTACC AAGAAGAAAA GCAATTATTC 360AGGATGGCAT CTTGCTGGGG AGAAGCAGCC TCCCTGAGGT AGATGTGTTC TCCTGTCACT 420TAAAGAACCA CTTCTCCTGG TCTGAGTAGT AAGAGGCGCA TTTGCTGTTG CTGCACCATT 480TGCCAAGGCT CTGAGTTTGA GGTATGGGAT GTATTAAAAC AATTTAATGA AGAATTAAGA 540TTCCATTCTG TCATTTTGAA CACAGGGTTC AGTCCTATAT TATTCACTTG AGAGGACTGG 600TGAGTTTGAC TTTCATTTCT TTTTTACAAC TGGGAAGGGC AAATTACACA TAAAATGTCC 660CAGTGGAAAG GGGTCATGTG TCGAAATCCC CACTCTTCTG TCTCACCTCT CCCTGTTGTT 720TTAAACTGGG GCTCATTAAT ATAATTCTAT GGGGATCACA CCTTTGAAAT TCATGAGGAC 780AGTAAGAGAG CAGAAAAATA CACAATAATA AGGAAAGGAG CTTCCATTAT TGGTTTTTAA 840TGAGCGTACT TGAATTACGG CCACTGCaGT TTATGGATAT TTTTTGTTGT TCATTTGTAT 900GTGTTATAGT TAGAAAAAAA AAGAATCCTA GCCAAGGGAC TTGAACCAGA GAGAAGCAGA 960AATTGACTTA AGTAGGAAGG GAAACACATT ATTAGATAAA GTCAGGTCCT GGGCTTCCTC 1020GGCTTGTTTT GGGTGGAGTG CCTGGGGACA GGCTGAAGCC CCTGTGTGGG GTGGTTTCCT 1080TTGCTGAAAA GCTGGGCTGG AAGATGTTGT GCTCAGTGCT CAACCTCATG CACCCTCGCG 1140AGGCACAGGC AACGGGTGCT CTGGGAAACA CACGTTATGT ATCATAGCCT CTGTTTGTCT 1200GTGGGATTGA TATCCAATAA TAACTTTGGA GAAAAATAAC TCCTCTTATT TTGTTAGCCA 1260CAGCCCTGGG CCAGGGAAGG TGGAGAATCA GTGAAAATGC ATTTTGTTTG TTTCTCTAGA 1320AGTTTATGGT GCAGAGTCAA ATTGAAGGCA AATGAGGAAT ATTTTTTCAT TAAATAATAA 1380CTCAACTTGC AAGTCTTTTT TGCTTTTGTT TGTAGTTTCT TCTTTGAACT TAATTTTCAG 1440TTAGTAGGAG GGGTTAGAAA CCTGAGCTAT TGCTAAAGCC CTTGATATGA ATGAAAGAAG 1500CAGGTGCAAA TCCCCTCACA GAGAGAAACC AAAGGGTCCT GGCTATGGAT ATTGGTCACC 1560TAGTCAGGAT GCTGTTGTGG GTCTTTATGA GATGATGAAT AGGGTGGCTT TGGATGCATT 1620AATGATATTT ACATGCTCCT TCTGTTAGTG TCCTGTGCCC TGACCCTACA AGATGCCAAG 1680AGAAGATGCT CACTTCATCT ATGGTTACCC CAAGAAGGGG CACGGCCACT CTTACACCAC 1740GGCTGAAGAG TAAGTTCAAA ACCAGACCCA GCAGGGCTTC CAGTTTGCCG TTTGCTGACA 1800CAGCCTGCTG ACTTCCACCA GTACATGCCT GCTCGTAAAT CTCCCTAGTG TTTATCTCCC 1860CAGACAGTAA CATCCCTGGC AACAAGGGGA GGAGATTCTG TGCTTCTATA AGGGGCTCAG 1920TCAAGCTTCT CTGAGGCCAA ACAGGCAGGA AGATGGGAAT GGTATAAGGT TGGATCTTGC 1980CATTTTTGGG TGCACTTTTG ACTATTGGGT CTTATCTGTA GGTTCCCAAG TGGAAAAACA 2040TCTGTTCAGG ATCACAATGC CTCTCTCCTC AATCCTTGTT CTGTCTCCTC CACTCAAATT 2100CCTGAAGGTG GTTTGCAGAC AGAATAAAAG TGAGTTGCCA AGGAGCCAGT AAGGATGACG 2160GGCAGGTGTG TGTGACTCAG CCCACAGCCA GACTCGAGAG GAAGATGGAG GTCACAGCCT 2220TTGCAGTATA ACTTTATCCT AAGGAAAGAC ATTGGGTTTT ATGAGTGAAT TAAAAATAAG 2280TATTTATATG ATTAAGCATT TCTAAATGCT AAGCATTGTA TACTGGCGTG AGACACTGTT 2340TTTATCTTTG AAAAAACTCA CAACTTAGTG GGAGAGTTAG GCATGAGATT AATTTCAGCA 2400AATGTAAGTG CGGTAATGAA AACCCAGAGG CTGCAGGGAC ATACTCTGTA TGTGCTGGGA 2460GTGGGAAAGG GACATACTCT GTACGTGCTG GGTGGCAGGG GCAGGGGAGG CCCCACCCTC 2520TGCGTGGGAC TGTAACAGGA CAACACCCTC TTATGTGGTC TGTCCAGAAC TCCCTGTGAA 2580CCTGCTCTTT CTTTGGAAAG AGCTGTTGAA CAATCTTTGT TAACAGTCAA CCGCAGGACC 2640AGCAAGATGT AAAGCCCAAC AAAGGCACTG AGGAAGAGTT CAGGAAGACA GCATTTCCTC 2700AGAAGACCCT GGTATAGGAT CCTCTAATAT CCCTGGCCAA TTGGAGATGA GGGCGGCGGT 2760ATCCTCTCAG AAAATGTCCT GACAGCAAAA ACATACTCTT TGAGGGAGGG GAGCCCATTG 2820CCCGTGCTAT TAGTTAGGGT ATCGTTTCAG CTTGTGTATA ATCACTCAAC AGACTCTTTA 2880AAATATACTT TTATGTCTCG TGTAAAAATT CAAGAGTAAA GAGTTCAAGG CCTGTTCGTT 2940TTCTTCTTGC TGGTTACTCC CTTGGGATCG TCACTTTTGT CCCCATGGCT GAAGATGTTG 3000TGCCATCACC TCCACATCTT GCCAACAGAA AGCAGGAGGT GAAGGAGAGG CTAGGACCAT 3060TCCTTTCAAG GGGCACACGT CACTTCTGCT TATTGCTCCA CCCCCGCCCC CCGCCCCGTG 3120GCACCCACCC TGGTGGTATC ATTCTTGCTG TGTTGTAAAT GAAGAAAGGT TTAGAGAAAT 3180TAGGAAATGT GTGGCCAGAC ATGGTGGCGC TGGGATTTAA ATCCAGGTCT GTTTGCCTCC 3240AGAGTCCATG CTCTTAAGTG TTATGCTGCA GGCCAGCAGA GGCAAATATT TGCACAATCC 3300CATCCGACGA GAGGCTAGGG CAGAGGTCAG TATCTCTCAG TGTGAAGCTG GAGGCTGATG 3360CTAGTCAGCT CAGTAGGCCG AAAGTGGAGT TGTCCTTTGC CATGTAGGGC CATCATGCCC 3420AGCTGGGGAA CCTCATAGCC AGGTGTACCC ACAACCTGAA CAAGGTAACT TTCAGGGTCT 3480AGTCAGGAAG AAACCAACTA GATGGTTCAA CATAGAGACT TTAATATAAG AAGCTGGTTA 3540AACAGGCATG GGACTGAGAC TGAGGAGGCA AAGAAGGCAT CGGGGCAACC AAGGCTGTAC 3600CCACAGAATG CTGCTTCTAC CCCCGTGTCT GGGGTAACAA ACGGAAGGGT GAGGCCATCA 3660GGACCTAGAG TTGGGAGGAG GGACGCCACA GAAATGGGAC CCAGATCTCT AAGGAGAGAT 3720TTTTGTTTGG CTGGTTCTGG TGTCTCAAGA GCTTAGAAGT GAGGGGCATG AATCAAATAC 3780TCAGGCCTCT GAGGTCAGCC AGTGCTCTGC TGGGGAGGGG CATAATGAAG CTGGCTCTGA 3840CAATGCCGGA AAACGAGCTG GTGCTTGGCA TATACAGACA ATGTGAGCAT TGCTGGGGTG 3900ATCCTGACAG GAGCCAGAAG CACACTGGAA GGAGCTGCTC CTTCTTGATG CCCCAGGTTT 3960GTAGGCACCC TCTAGAGTAC TCTAATGGGA GCCAGTGGGC AAAGGAGAAG TGGCATTTGC 4020AGAGTCCAGT CCCAGCATCA CAGAGCAGAG CATAGAAAGG TAGGTTTGGA GAAGAGGGAC 4080AATGGCTTAA TAAAGGGCAA AGGGGGTTAT GACCACTATC ATGTGAAGGA ACCCCTTGAC 4140TGAAGGCACA AGCTTTCTGT GTCTTGCAAC CTGAATGACG TGCATAAGCA GGGTCAGGTG 4200GGTTATCTGA CATTTTCCTT GAGAACAAGA GGGAGCCTCT GGATTCCAGC ACAAAAGAAA 4260AATACCCACT CAACCCGTAT GCGTGGGAGC TATCCTTTAA AGAGAAAGTA ATTCCTTTTG 4320ACATTTTGCT GTCTGTAGAA GGGTCAGATG GCCAAAGCTT CCAGCACAAT GAAACACTTA 4380ACTTCAGTCT GTGAGTGTAG GAACCCCTGA ATACATGGAA CATCATCATC TTGTGCAGGT 4440ACTGAAGGAG ATCGGTCCAG AAAATAAGTA ACTGCACATG GCCACCAATG TCAAAAGTCA 4500TTCCTCTCAT GAAAAGTCCC TGCCCCCATT GCTGTTTGTT TAAATAGGTG GGATGGAGGT 4560AGGGGAATGG GGCCATCTTC TTTTTTTTTT TTTAATTTTT TTGCATAAAA TCCAGATCCT 4620GCACAATGGG GCAATCTTCA TTAAAACAAT GCATCCCTAA GATCTGAGAA TATTTATCCT 4680TCTCACAATT GTGCCAGCAG GTGGAATGAA GAAGAATGAT GCAAAATAAG TTCCCACATC 4740CAGCCAAGAA GGACTACATA CCTGCTTTGG GTATTATGTA TCCCTTTGAA ACCTCAGTGG 4800AGAGCAGTTC TCACAGTTGG GTGGACACAA GTCATCCATG GAACTTGTTA AAATGCAGAT 4860TTCTAGGTGC TGCCACCTAA GAGGCTGATT GGGTAGGCCA GGGGTGGAGT CCTATGATCT 4920GCACCTTAAC GTGCATCTCA GGTGATTCTG CTGCAGGTGG TATTTGGAAG ACACTCTGAG 4980GCGCCCTGCC AAGCTGGGCA GTGGGTTCTT CCAATGTGTC AGGCATACCC TGGTGCTTTT 5040CGCTCTCAGT CACTTGGGCA TGTTGTGAGT ACCACGTGAC CATGCATAAA GTGCTGTAAC 5100AGAGCTCTGT CTGTGTCAAG ATATTCAAGT GGACGCCACA GGGTAAAATG AGAGCACAGG 5160CATGTTGGGA GTTGAATCAG CTGCCTTCAG TCACGAGAAC ACACTGAACA CTCCTTGTGA 5220CAGCTTCAGT TCAGGAAAGA GTGACTCTGC AGGAAAAGCA CTGGCCTGGG AGACCTGGAT 5280CTGGCCCAAA TTCTGGTGCT CACTTGCTTG GTCTCCCGTT CCAGTTGCTG TGAATGTTGG 5340TTCTGCCACT TGCTGGTTGT GCAGCCCTGG GCACTTGACC AGCATAATGT CAGCTGTAAA 5400ATGAACATCA TTCCTAACTC CGAGGACTGT GGTTAGGATG AAATAAAAGC ATATATGTGG 5460GGGTGCCTAG CCCAGTGCCT GGCACAAATT GGTGCTCAAT GAATGGTAGT CACTATGGTT 5520ATGGTAATGT TGATGAATCT TCATAGGTCT CAGCTTCCTG ATCTATAAAG CGGGTGGACT 5580GACCTACATA AGTCAGAGTT TCCATCTAGC ACTGTCATCC CATGGTTCGC TCTATCCTGT 5640TTGGAGACGG ACAGGATAAG CTTGATGTCT CCTCAGCCTT GAGACAGAAG TTGTCCAGTA 5700GATGGTACTG AGCAAAAGTC TCTCCAGCAG AAGCCTTAGT TAAACCTTGC TTCTCCTGTA 5760GCTGCTCAGT CTCTTGTAAG TCACTCAGCT CTGCAGAAAC TTTCTTAGCG AGTTGACAAC 5820CACAGATAAC AGAGTCAGTT CTGTCGATTT TGATCATGCT GTGATCAGGC AGATGTTAGC 5880TAATTGATGA TGCTTGCCCG GAGTGAACAG CTCCAGGCCC TGTTTCCAGG GTCTTTGTGG 5940TAACTTTGTG GTAACTGTAA TGCTTCCCAG GGGTCACTGA ACACAGGGCC CAAGAGGCTG 6000GTGTAGACCC CCAGATTGGC ACCCTGCTGC TTAGACAAGA TCCTTCTCAA TAAGTAATGC 6060CATAGCTTTG CTGTAGGTTC AGCCCAGACA CTTCTCCCTA GGGCTGCAAG GAGCAAAGCG 6120GGGAGTTTAG GGAAGGGAGG GCACGAACAT AATTGAGACG GATTCAGGTT CAAATCCAGC 6180CTCTGTTTTG TGCTAGCTCT GTATGATCAC CAGCGAGTCA TGTATCCTCT GCCTTTTATT 6240TCCTCTTCTG TGAAAATAGG GGATGATAAA TTGTGTCTAC CCTCCAGTGT TGATGTGAGA 6300ATTGAATAAG CTAATGAATG TTTAGCACAG CACCTGGCTT TTAGTAGATG AGTCAGTGTT 6360AATTTCTATT TTCTCTTTGT GGGCTGAGTT GGAGAAAATG TTTTAAAACA GCCTGATGAG 6420AAGAAAAGAT AATTTAGCCC CAATAAATAC ATTGTCCACA TAAAGACAGT TACTATGGCA 6480CTTCTCATAC CTGGAACTTG GGTGCCTGGG CCATGCAATT AGCAGAGTTC CTGTGGGCAC 6540ACACTTGAGA GGCTCCTAAA GACCTGGGTT AGATCCAGGT GCTGGAGGCC TGGTGGGGTG 6600CCAGTGTGGG AGGTGGGAAA CTACTTGGAC ACTGGGAGAT GCTGCTCTGG GTCGTCAAAG 6660TCCATATGAA GAGGAAGACT GATTTATGCT TCATCATAAT GTAGAACAAT GTTTCAATGA 6720CAAAGTGGAT TTGTCTATCT CTTGGGCCAG GCCGCTGGGA TCGGCATCCT GACAGTGATC 6780CTGGGAGTCT TACTGCTCAT CGGCTGTTGG TATTGTAGAA GACGAAATGG ATACAGAGCC 6840TTGATGGTTG GTAAAGTTCC CACTGCTGAA ATCCCTCCAA GTCCAGGGCC CTCTTTCCAG 6900TTCTTTCCTC TGAATCTCTG GAGAGTCAGA TAATTGCCTC ATTATAACCT TCAGCTCTGA 6960TTCCGGCTTC TGATGCCTCT TTTGCTACAT TGTACTTTGG CAACTCTACC TTTGCCTCTG 7020CTCAGGCATG AACCTCAACC AGGAACTTGC CCTGTGTCTT AGTCTGTGAT TATAACATAA 7080TACGAGAGAC TGTAATTTAT AAATAAATGA AATTCATTTG GTTTACAGTT GGGAGGCTGG 7140GAACTCCAAG ATCTAGGGGC CACACCTGGT GAGGACTTCT TGCTGTGTCA TATCATAGTG 7200GAAGGCATCA CATGGGCAAG GGAGTGAGAG AGCAAGAGGG AGCTGAACTC ATTTTTTTTT 7260TTTCTTGAAA CAGGAAATCC TGGGATGGAG CGCAGTGGTG ATCATGAGTC ACTGTAGCCT 7320TGACCTCCTG GGCTCAAGCC ATCCTCCTGT CTCAGCCTCC AGAGTAGCTG GGACCACAGG 7380CACGTGCCAC CACACCGGCT AATTAAAAAA AAACTTTTTT TTGTAGAGAC GAGGTCCCAC 7440TATGTTGCCC TAGGCTGGTC TCAAACTCCT GGGCTAAAGT GATCCTGCCT CGGCCTCCCA 7500AAGTGTTGGG ACTACAAGTG TGAAACACTC CACATATGGC CCAAACTCAC TTTTATAACC 7560AACCTACTTT TGCAATAACA AACACACTCC TGCAATAACA CAATTAATCC ATTCGATGAG 7620GACAGAGCCC TTGTAACTTA ATCGACCTCT TAAAAGTCCT GCCTGTTACC ATTGTTGCAT 7680TGGGGATTAG GTTTCCAATA CACGAATTTT GGGGGACACA TTCAAACTAT AGCACCTGTC 7740TCTTTGGTTC TACTCATAGC AGACTTGGGT ACCTGGATGT TGTGTGTAGC TAAGCACTGA 7800CGGTTTATAG GGCACAGGGG AAGGGGTTTG AGGTTCCCTT ATAGCAAACA GGAGTATATT 7860AGACACCTCA GGTTTTACCA CTTCTGGGAA TTCTTGCTGG TTCTGTTACT CCACTTTGTG 7920ACCTGCTCTT CCTACTTTTC TTCTTCACCC CTTTCCTCAC TGGTTACCTG TGAATTCCAA 7980GTTCTTCTGA CTCTACACTA AGCATCCCAG GATATCATCA GTGCGATGAG GAAACCATCC 8040TTCCTGCATC AGCACAAAGG GTCACTTGTG TGTTTTTTAA CAGGCTGCAT CCTTCTTAGA 8100TGGCCAAAGG TTTTAATAGT ATTTTTTTCT TCTTTACCCA AATATGCAGG AAGCTAACAC 8160AATTACACAA TCCAATCTTC TGGTACCAGT ATCCTCCATG AATGGGAAAC ATCAACTGAG 8220TTTATAAGCT ATAAAAATTA CAGGTTTCAG CAATCTTGCT TAAAGCCAGG TAGCACTTCA 8280GCACTTCAGC ACCCGAAGCA TTCTCCATAG ATCTCGCTGT CTCTCTTTCT TGTTATTACA 8340GATCTGAAAG CTTTTCAGGT TGATGCATAA TGGAAAAAAA GTATCTTTCC AAAAGATGTT 8400GGAAAGTCCC ATTCTCATTC AGCAAGCACT TCATTTAGAG GAAAAGGTCC TGTGAAAGAG 8460AGGAGGGTTG GTGTGGGGTG GGGATTGAAG CTTGGCAAGC TGATAAGGAG AAGGTGAGAG 8520ATACAACTCT GGATTCTTTC CCTCTTTGCC AAGAAACTTG GGCAGTCTCA TGTCTCATGT 8580CTCCTGTTCC CCAATGTCTT TCCAGAGCAT AAATACAAAT ACAAACCATC AAAGGCAAGT 8640CAAGTCTGGG GGCTGACACA CCCACCGAGC ATAGCCCTCT AGTGTGCTGA CATCTAGTGG 8700GAAGGAGGAG GAGTTGATGA ATCTGAACAA GACTCCAATA TTGGAGGAAA TACTTGAGGA 8760AAGCCTTGGG TTAGAAAGTT AGGGATAGAA TTCCTGCTCA TACGGCTGTC CACAACAGGT 8820TAGTAGGGGA GGACTTTAAT CTCTGCCATA GAACTCCATT TGTAACTCTA GCATGGGGTT 8880ATGACATTGC CTTGTAATTG GCTATTTACT TTTTGCCTCT TCGACCCCTC CGCTTTCCCC 8940TATGTATGAA CCACAACAGA GAATATTTCT AACTCATCTT CATATCTCCA GTGCCTAGCA 9000CAGTGCCTGG TACATGGTAG TCACTCAATT GTGTTGCATT AGGACTTGGT CCCATTGTCT 9060GCCATTGAGT TGCTTGGAGA CTAGAATTCA ACTTCTCCAA GATTCACTAG CTCTATTTTA 9120CACCCAGACA TGTTGGAAAT CTGTGATGTA ACACAATGTA TATCCATTTT TATTTAATAC 9180ATATTTTCTT CTATATTTTG ATTTCATTAT ATATTTGTAT ATCAAAAACA AAATGTTTAG 9240TCTTTCAAGA AGTAAAGCTA TACAAACTCA ATATGTTGGT ACTCATTTCC TAACTATAAT 9300TATTAGTTTG ATCCTATTGA ACACAAATGC AGTAATTTTT CTTTTCTGCT TCAATGCTCT 9360CATCTTAAAT TCATTTAATT GAAAAATAAC AGAGAGTCTT AATGTCATGT GCTCAGACAC 9420TNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNGAGT GCAGTGGTAT GATCTGGGCT 9480CACTGCAAGC TCTGCCTCCT GGGTTCATGC CATTCTCCTG ACTCAGCCTC CCAAGTAGCT 9540GGGACTACAG GTGCCCGCTA CCATGCCTGG CTAATTTTTT GTATTTATAG TAGAGATGTC 9600ATTTCACTGT GTTAGCCAGG ATGGTCTCAA TCTCCTGACC TCGTGATCCA CACGCCTTGA 9660CCTCCCAAAG TGCTGCGATT ACAGGTGTGA GCCACCGTGC CCGGCCTTAT ACTTCTTTTT 9720TACTTTTTTT CAGTGGTTTC CCTAGAGTTT GCAACATACA TTTACAACTA ATTCAAATCC 9780ACTTTCAAAT AACACTATAC CATTTCATAG GCATTATGAG TATCTTAAAA TAATCCTAAT 9840TCCTTCCTCC TGTAAACTAA AAACAAAATC CTAAATCCTC CAAACAACTG AATGGACCCC 9900CTCTTCACCA AGGGGACCCC AGGGAAACCT GAAAAACTGA GTGTTGGCCA TGACGGGAAG 9960GGAGGTGAGA GATGCTCATT ATACTCCCTC CCTTTTAGAG TTTTAGGTAC AACTGACCAG 10020CATTAATTTT AAAATAGAGA TTACAGGACT GACAGAATGA ACTCTTTGTG GCAATATCAA 10080ATTAGGAACA AGACAATGCA AGGAAAGGGT TAAATCATGC CCTTCAAACC ATAAAAAAAT 10140TTTTTTTTAA TTAACCCCAT ATAATGTGGT ATACTTTCCA AACTGACTCT GGTATAGCAT 10200CACATGACAG ATTGCAGACT CCCTTACCTT AAGCATTCCT TTATACTGAC TTCAAGTCTT 10260AAGACAGAGC TGAACTCTTT CAACCAGCTG CTAACTAAAG AATACCTAAA ACCCACCTGT 10320GACTTGTAAG TCTCTGCTTT GCCATGTCCT GCCTTTTCAG GCTGACCCAA TGTATACCTT 10380CCGTGTATTG ATTTATGATT TTTACCTACA ATTCCTGTCT TCCTGAAACA TATAAAACCA 10440AATCATAACC CAACCACCTC AGGCACACTT TCTCAGGACC TCTTGAGACT ATTCTCCCGG 10500CCATGGTCAT TCATATCGGC ACAGAATGAA ACCTCTTTAA AATATTTTGC AGTTTTTTTC 10560TTTCTGTTAA CATTCCTTTC CCTTGTATCA TTGCTGTTAT TAATTTCAAG TATATATAAG 10620CATACCTAAT TAAATACATT GTTGCTATTA TTCATTTTTG AACAAACTAT TATCTGTTAA 10680ATCAACTAAG AATAAGACAA ATATGTTGGG TGCAGTGGTG CATGCCTATA GTCTCAGCTA 10740CTCAGAGGCT GAGGCAGGAG GATTGCTTGA GCTCAGGAGT TTAAGACCAG CCTAGGCAAC 10800TTAGCAAGAT CATGTCTCTT AAAAAAAAAA AAAGAAAGAA AGAAAAACAA AGTTTTAGGA 10860GGCTGAGGCA GGAGTATCAC TTGAACCCAG GACGCAGAGG TTGCAGTGAG CCGAGATCGT 10920GCCATTATAC TCCAGCCTGG GCAACAGAGT GAGACTCTGT CTCAAAAAAA AAAAAGAAAA 10980GAAAAGAAAA GAAAAAAAAA GTTTTTATTT TACCTTCACT TATTCCTTCT TGGATGTTCT 11040TCCTTTATGT AGGTACAAGG TTCTGACCTA TGTTATTTTC TTTTTCTCTA AAGAACTTCA 11100AAAGTTTCCT GCAAGGCAGG TCTACTGGCA ATGAATTCCC TCAATTTTTG CTTGACAAAG 11160TCTTTATTTC TGCTTCACTA TTGATGGATA ATTTCACAAG AGTGTTCCTT TTGTAGATTC 11220ACTCTTCTTA TCCTTCCCTT CAGAAATATT CTTTGACCAA CTATTGGGTC CCAGGTACTG 11280CACTAGAGCT TTACTTCTAG TTAATTCCCA CAGCAATTCT GAGAGGTAGG TAGGTATTAT 11340ATTCCTAGAT GCAAACTCAG AATTCAGAAG GTAAAGTGAT GAGACTGAAG GCACACAGCA 11400AGTAAGTGGC AGAACCTAGA TTAAAACTCA TTCTTAAAAC TTTGGCTTCC TTCTCTTTTC 11460TTTAATGGAT TCAGTTACTT CTTCTCACCC ACTCACCTTT ATCAATTTAC ATTTCAGATA 11520AAAGTCTTCA TGTTGGCANC TCAATGTGCC TTAACAAGAA GATGCCCACA AGAAGGGTTT 11580GATCATCGGG ACAGCAAAGT GTCTCTTCAA GAGAAAAACT GTGAACCTGT GGTAGGTTAA 11640GATCCTTCAT AAGGGTATTT TCATGAATGG CTGTTTTTAA CTCAAGTGAA TACAATTATT 11700TCCATTTAAA AAGCAAGGAC AATGTGAATG TACTCATTGC CACTGAACTA TATACACCTA 11760AAAATGGTTA AAATGGCAAC TTTTATGTGT ATTTTATGAG AATAAAAAAT AAATAATAAT 11820AAAAAACAAG GGAAGTACAG ATATTTTCTT AATTGTGTTG TCACATACCC AGTGTTTCCA 11880GGGTCAATAA TGAGAGCCCT ACATGTAAGA TTCAAAGGAA GAATTTAGTC CTGGATACAA 11940TATTCTTTTA TGTTTTTAGT TATATTTGCC TTTTTAATGG ATGCAGATAT ATACAGAGGG 12000AAGGGATAAA GTACCTATTA TTTATTGTAT AGAGCTGTGC TGTCTGATGG CTTAGCCACT 12060AGTCACATGG TGCTATTGAA CACTTAAAAC ACAGGAGTTT GAAATAAGCA TGTATTATAA 12120TACATATCAT ATTTCAAAAA TATTAGTATG TAGAAAAGAA GATAAATGGT TCATTAATGA 12180TTTTTATATT GATTCACCTT GAAATAAATA TTCTGAAAAT ATTAGGTTAA ACAAAATATT 12240TTAAGATTAA TTTTACATGT TTCTTCTTTT AAATGTAGCT ACTAGAAATT TTAAAATTAC 12300ATATGGCTGG GCATGGTGGC TCACACCTGT AATCCCAGCA CTTCGGGAGG CCGAGGTGGG 12360TGGATCACCT GATCTCAGGA GCTCGAGACC AGCCTGGCAA ACATGGTGAA ATCCTATCTT 12420TACTAAAAAT ACAAAAATTA GCCAAGCGTG GTGGTGCATG CCTGTAATCC CAGCTACTTG 12480GGACGCTGAG GCAGGAGAAT CACTTGAACC CGGGAGGTGG AGGTTGCAGT GAGCCGAGAT 12540AGTGCCACTG CACTCCAGCC TGGGAGACAA GAGCAAAACT CCATCTCAAA AATAAATAAA 12600TAAAATAAAA TTACATAAGT GGCTTGTACC ATATTTCTAT TGGACAGCAC TAGTACATAT 12660ACAACACAGC ATAATGGTTG AGAGCACTGA CTCTGGAGCC AAATTACTGT GTTTGATTCT 12720TAGCTCCACA ACTTACTAGT TGTGTGACCA TGGGCAAGCG AGTTAACCTC TCTGTGCCCC 12780AGTTTCCCAT TCTGTAACAT GAAAATAATA AAAACACTCC CCAGAATTGT TGTGAGCATT 12840AAATGAAGCC CTGACACATT TGTTCTGGAT ACAATATCCT CTTGTTTTAT ATTTGGTAGT 12900ATCAATGTGC CTTTAGACAC AATTACAACG ATCTCTGTGG TAAAGATGCA ATGTATATGG 12960TGTCTATAAA TAGCATTCAA TGATTCGTTA GTTAGGGCTT GAGACTTTTA CTGTCATGGA 13020AAATCTAGGT ATAGCTAAGC TTTTGAGATT TTGGGAACTC CTTAACCCTA TTTTTCTCTA 13080CTCTTGCCCC CAACAATCAG CCTATATACT TGTGAAATTT AACAATTACT TCACTGGGCA 13140GAAATTATAT GGGAACACTT AGAAATTTCA GTCCACAGGG AAAGTATAAA TATGTTAACT 13200ATTTTAACTT AATCCCTTCC TAGAAACACA TACACTGTTG CCAAGCCCAT ATTCTCCCTT 13260TCTTGTTCTC ACAGTTCCCA ATGCTCCACC TGCTTATGAG AAACTCTCTG CAGAACAGTC 13320ACCACCACCT TATTCACCTT AAGAGCCAGC GAGACACCTG AGACATGCTG AAATTATTTC 13380TCTCACACTT TTGCTTGAAT TTAATACAGA CATCTAATGT TCTCCTTTGG AATGGTGTAG 13440GAAAAATGCA AGCCATCTCT AATAATAAGT CAGTGTTAAA ATTTTAGTAG GTCCGCTAGC 13500AGTACTAATC ATGTGAGGAA ATGATGAGAA ATATTAAATT GGGAAAACTC CATCAATAAA 13560TGTTGCAATG CATGATAAAA AAAAA 13585(2)SEQ ID NO.52的信息(i)序列特征:
(A)长度:648bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.52AGCTGCCGTC CGGACTCTTT TTCCTCTACT GAGATTCATC TGTGTGAAAT ATGAGTTGGC 60GAGGAAGATC GACCTATCGG CCTAGACCAA GACGCTACGT AGAGCCTCCT GAAATGATTG 120GGCCTATGCG GCCCGAGCAG TTCAGTGATG AAGTGGAACC AGCAACACCT GAAGAAGGGG 180AACCAGCAAC TCAACGTCAG GATCCTGCAG CTGCTCAGGA GGGAGAGGAT GAGGGAGCAT 240CTGCAGGTCA AGGGCCGAAG CCTGAAGCTG ATAGCCAGGA ACAGGGTCAC CCACAGACTG 300GGTGTGAGTG TGAAGATGGT CCTGATGGGC AGGAGATGGA CCCGCCAAAT CCAGAGGAGG 360TGAAAACGCC TGAAGAAGAG ATGAGGTCTC ACTATGTTGC CCAGACTGGG ATTCTCTGGC 420TTTTAATGAA CAATTGCTTC TTAAATCTTT CCCCACGGAA ACCTTGAGTG ACTGAAATAT 480CAAATGGCGA GAGACCGTTT AGTTCCTATC ATCTGTGGCA TGTGAAGGGC AATCACAGTG 540TTAAAAGAAG ACATGCTGAA ATGTTGCAGG CTGCTCCTAT GTTGGAAAAT TCTTCATTGA 600AGTTCTCCCA ATAAAGCTTT ACAGCCTTCT GCAAAGAAAA AAAAAAAA 648(2)SEQ ID NO.53的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.53Ala Leu Ser Arg Lys Val Ala Glu Leu
5(2)SEQ ID NO.54的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性 (ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.54
Phe Leu Trp Gly Pro Arg Ala Leu Val
5(2)SEQ ID NO.55的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.55Thr Leu Val Glu Val Thr Leu Gly Glu Val
5 10(2)SEQ ID NO.56的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.56Ala Leu Ser Arg Lys Val Ala Glu Leu Val
5 10(2)SEQ ID NO.57的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.57Ala Leu Val Glu Thr Ser Tyr Val Lys Val
5 10(2)SEQ ID NO.58的信息 (i)序列特征:
(A)长度:11个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.58Ser Thr Leu Val Glu Val Thr Leu Gly Glu Val1 5 10(2)SEQ ID NO.59的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.59Leu Val Glu Val Thr Leu Gly Glu Val1 5(2)SEQ ID NO.60的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.60Lys Met Val Glu Leu Val His Phe Leu1 5(2)SEQ ID NO.61的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.61 Val Ile Phe Ser Lys Ala Ser Glu Tyr Leu1 5 10(2)SEQ ID NO.62的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.62Tyr Leu Gln Leu Val Phe Gly Ile Glu Val1 5 10(2)SEQ ID NO.63的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.63Gln Leu Val Phe Gly Ile Glu Val Val1 5(2)SEQ ID NO.64的信息(i)序列特征:
(A)长度:11个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.64Gln Leu Val Phe Gly Ile Glu Val Val Glu Val1 5 10(2)SEQ ID NO.65的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.65
Ile Ile Val Leu Ala Ile Ile Ala Ile
1 5(2)SEQ ID NO.66的信息(i)序列特征:
(A)长度:11个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.66Lys Ile Trp Glu Glu Leu Ser Met Leu Glu Val1 5 l0(2)SEQ ID NO.67的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.67Ala Leu Ile Glu Thr Ser Tyr Val Lys Val1 5 10(2)SEQ ID NO.68的信息(i)序列特征:
(A)长度:10个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.68Leu Ile Glu Thr Ser Tyr Val Lys Val Leu1 5 10(2)SEQ ID NO.69的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:M3-195.203或者SEQ ID NO.69:Ile Met Pro Lys Ala Gly Leu Leu Ile
5(2)SEQ ID NO.70的信息(i)序列特征:
(A)长度:9个氨基酸
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:M3-220.228或者SEQ ID NO.70:Lys Ile Trp Glu Glu Leu Ser Val Leu
5(2)SEQ ID NO.71的信息(i)序列特征:
(A)长度:14个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.71Ile Asn Phe Thr Arg Gln Arg Gln Pro Ser Glu Gly Ser Ser
5 10(2)SEQ ID NO.72的信息(i)序列特征:
(A)长度:12个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质 (xi)序列描述:SEQ ID NO.72Leu Phe Arg Ala Val Ile Thr Lys Lys Val Ala Asp
5 10(2)SEQ ID NO.73的信息(i)序列特征:
(A)长度:12个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.73Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr
5 10(2)SEQ ID NO.74的信息(i)序列特征:
(A)长度:1896bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(xi)序列描述:SEQ ID NO.74GCGGCGGTGG CGGAGGCGGA CACATTGGCG TGAGACCTGG GAGTACGTTG TGCCAAATCA 60TTGCCACTTG CCACATGAGT GTAAATGATG GCGGATGCAA GTATGTCCTC TGCCGATGGG 120AAAAGCGATT ATGGCCTGCG AAGGTGACAG CCATTATTCT GTAACTTCAG GACTTAGAAA 180TGACTTTCGG GTGACAAGTA AAATCTTGAT CAGGAGATAC CTAGGATTTG CTTCAGTGAA 240ATAATTGAGC CAGAACACGG TTGGCACTGA TTCTCGTTCC CCATTTAATG GGGTTTTGGT 300CTAGTGCTTC CAAGGTTACA CTTCCAGAAA TGTCTTTTTT TTTTCACACT AAAAAAAAAA 360AAAAGAATCA GCTGTAAAAA GGCATGTAAG GCTGTAACTC AAGGAAAGAT CTGGCAAGCA 420GCCCTGTGAT AGTAAATTAT GGTCGTGTTC AGGGAATGCT TTCCAGCAAT TCAGTAGACA 480GTGCTCAGCT GCAATGCAAA AGCCCAGGTC CTTGTCTTTG TCTGCCACTG GCCTCTCATG 540CCTCAGTTTC CCCATCTGTG AAACAATGGG GATTGGACCA AATATCTGAA ATCCCATGGT 600TATAGGCCTT CAGGATTACC TGCTGCATTT GTGCTAAAGT TTGCCACTGT TTCTCACTGT 660CAGCTGTTGT AATAACAAGG ATTTTCTTTT GTTTTAAATG TAGGTTTTGG CCCGAACCGC 720GACTTCAACA AAAAATAAGA GAAGAAAGGA ATATTTTCTA GCTGTGCAAA TCCTCTCCCT 780AGAGGAAAAG TTAATTGTTG TGTTGTTTTA ATACTGTTTT TTCCCGTGTA GATTTCTGAT 840ACTTCAATCC CCTACTCCCC CAAAACAGTT GAAGCCCAGC CCACTCTTAA TGGGCTTATT 900CACCATTTGT GTAATTCATT AATGCTCATA ATAACCTCAT GAGAAAGCAA CTAGTTTGAT 960TTTATGTCAG TTTGGAAGCT GAAGATCCAA ACGAGGCATT CTGTGAGATC TATGGAGAGA 1020TTGGTACAAA CACTGAATAC ATGTAAATTA TACTCAGGGT AGACCCTATT TGTGGTTAAA 1080ATAGGGATAT TTCCTTTTTT TTTTTTTTTT TTTTGACTGT TTCTTAATCA GTGCCATGCC 1140AGGAAAATAG GGATGTTTCC TTCCCAGAGA TCTGTGTGTC TTTTTTCAGA AACGTCTGTG 1200ACAGGCCCAT CAATTTTGAA ATATTTGGTT TTTGAGCCTG TCACTCTAAA CCAGCGTTTA 1260ACGTTCAAAA GGCAAATAAC TGATGACCAG GCGGCACATT GTTCTGCTCC GTGAGTGTCT 1320GGCACTGGGA AAGGTGTAGA TTGTCTAGAA TGACAGCAAT TCCGACGCCC CAGTCAGTCC 1380TGCGTGATTG TGGCGAGGGC GCGTCTGGCA CCGGGAAGGT GTAGATCATC TAGAATGACG 1440GCGATTCCGA CGCCCCGGTC AGTCCTGCGT GATTGGCGAG GGTGCATCTG TCGTGAGAAT 1500TCCCAGTTCT GAAGAGAGCA AGGAGACTGA TCCCGCGTAG TCCAAGGCAT TGGCTCCCCT 1560GTTGCTCTTC CTTGTGGAGC TCCCCCTGCC CCACTCCCTC CTGCCTGCAT CTTCAGAGCT 1620GCCTCTGAAG CTCGCTTGGT CCCTAGCTCA CACTTTCCCT GCGGCTGGGA AGGTAATTGA 1680ATACTCGAGT TTAAAAGGAA AGCACATCCT TTTAAACCAA AACACACCTG CTGGGCTGTA 1740AACAGCTTTT AGTGACATTA CCATCTACTC TGAAAATCTA ACAAAGGAGT GATTTGTGCA 1800GTTGAAAGTA GGATTTGCTT CATAAAAGTC ACAATTTGAA TTCATTTTTG CTTTTAAATC 1860CAGCCAACCT TTTCTGTCTT AAAAGGAAAA AAAAAA 1896(2)SEQ ID NO.75的信息(i)序列特征:
(A)长度:9个氨基酸残基
(B)类型:氨基酸
(D)拓朴结构:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO.75Glu Glu Lys Leu Ile Val Val Leu Phe
5(2)SEQ ID NO.76的信息(i)序列特征:
(A)长度:1554bp
(B)类型:核酸
(C)链性:单链
(D)拓朴结构:线性(ii)分子类型:核酸(ix)特征:
(A)名称/关键: DAGE
(D)其它信息:当V是C或A时,Xaa是Arg,或者当V是G时,
Xaa是Gly(xi)序列描述:SEQ ID NO.76VGA CTG AGA CCT AGA AAT CCA AGC GTT GGA GGT CCT GAG GCC AGC CTA 48Xaa Leu Arg Pro Arg Asn Pro Ser Val Gly Gly Pro Glu Ala Ser Leu1 5 10 15AGT TTC CGC AAA ATG GAA CGA AGG CGT TTG CGG GGT TCC ATT CAG AGC 96Ser Arg Phe Lys Met Glu Arg Arg Arg Leu Arg Gly Ser Ile Gln Ser
20 25 30CGA TAC ATC AGC ATG AGT GTG TGG ACA AGC CCA CGG AGA CTT GTG GAG 144Arg Tyr Ile Ser Met Ser Val Trp Thr Ser Pro Arg Arg Leu Val Glu
35 40 45CTG GCA GGG CAG AGC CTG CTG AAG GAT GAG GCC CTG GCC ATT GCC GCC 192Leu Ala Gly Gln Ser Leu Leu Lys Asp Glu Ala Leu Ala Ile Ala Ala
50 55 60CTG GAG TTG CTG CCC AGG GAG CTC TTC CCG CCA CTC TTC ATG GCA GCC 240Leu Glu Leu Leu Pro Arg Glu Leu Phe Pro Pro Leu Phe Met Ala Ala65 70 75 80TTT GAC GGG AGA CAC AGC CAG ACC CTG AAG GCA ATG GTG CAG GCC TGG 288Phe Asp Gly Arg His Ser Gln Thr Leu Lys Ala Met Val Gln Ala Trp
85 90 95CCC TTC ACC TGC CTC CCT CTG GGA GTG CTG ATG AAG GGA CAA CAT CTT 336Pro Phe Thr Cys Leu Pro Leu Gly Val Leu Met Lys Gly Gln His Leu
100 105 110CAC CTG GAG ACC TTC AAA GCT GTG CTT GAT GGA CTT GAT GTG CTC CTT 384His Leu Glu Thr Phe Lys Ala Val Leu Asp Gly Leu Asp Val Leu Leu
115 120 125GCC CAG GAG GTT CGC CCC AGG AGG TGG AAA CTT CAA GTG CTG GAT TTA 432Ala Gln Glu Val Arg Pro Arg Arg Trp Lys Leu Gln Val Leu Asp Leu
130 135 140CGG AAG AAC TCT CAT CAG GAC TTC TGG ACT GTA TGG TCT GGA AAC AGG 480Arg Lys Asn Ser His Gln Asp Phe Trp Thr Val Trp Ser Gly Asn Arg145 150 155 160GCC AGT CTG TAC TCA TTT CCA GAG CCA GAA GCA GCT CAG CCC ATG ACA 528Ala Ser Leu Tyr Ser Phe Pro Glu Pro Glu Ala Ala Gln Pro Met Thr
165 170 175AAG AAG CGA AAA GTA GAT GGT TTG AGC ACA GAG GCA GAG CAG CCC TTC 576Lys Lys Arg Lys Val Asp Gly Leu Ser Thr Glu Ala Glu Gln Pro Phe
180 185 190ATT CCA GTA GAG GTG CTC GTA GAC CTG TTC CTC AAG GAA GGT GCC TGT 624Ile Pro Val Glu Val Leu Val Asp Leu Phe Leu Lys Glu Gly Ala Cys
195 200 205GAT GAA TTG TTC TCC TAC CTC ATT GAG AGA GTG AAG CGA AAG AAA AAT 672Asp Glu Leu Phe Ser Tyr Leu Ile Glu Arg Val Lys Arg Lys Lys Asn
210 215 220GTA CTA CGG CTG TGC TGT AAG AAG CTG AAG ATT TTT GCA ATG CCC ATG 720Val Leu Arg Leu Cys Cys Lys Lys Leu Lys Ile Phe Ala Met Pro Met225 230 235 240CAG GAT ATC AAG ATG ATC CTG AAA ATG GTG CAG CTG GAC TCT ATT GAA 768Gln Asp Ile Lys Met Ile Leu Lys Met Val Gln Leu Asp Ser Ile Glu
245 250 255GAT TTG GAA GTG ACT TGT ACC TGG AAG CTA CCC ACC TTG GCG AAA TTT 816Asp Leu Glu Val Thr Cys Thr Trp Lys Leu Pro Thr Leu Ala Lys Phe
260 265 270TCT CCT TAC CTG GGC CAG ATG ATT AAT CTG CGT AGA CTC CTC CTC TCC 864Ser Pro Tyr Leu Gly Gln Met Ile Asn Leu Arg Arg Leu Leu Leu Ser
275 280 285CAC ATC CAT GCA TCT TCC TAC ATT TCC CCG GAG AAG GAA GAG AGT ATA 912His Ile His Ala Ser Ser Tyr Ile Ser Pro Glu Lys Glu Glu Ser Ile
290 295 300TCG CCC AGT TCA CCT CTC AGT TCC TCA GTC TGC AGT GCC TGC AGG CTC 960Ser Pro Ser Ser Pro Leu Ser Ser Ser Val Cys Ser Ala Cys Arg Leu305 310 315 320TCT ATG TGG ACT CTT TAT TTT TCC TTA GAG GCC GCC TGG ACT CAG TTG 1008Ser Met Trp Thr Leu Tyr Phe Ser Leu Glu Ala Ala Trp Thr Gln Leu
325 330 335CTC AGG CAC GTG ATG AAC CCC TTG GAA ACC CTC TCA ATA ACT AAC TGC 1056Leu Arg His Val Met Asn Phe Leu Glu Thr Leu Ser Ile Thr Asn Cys
340 345 350CGG CTT TCG GAA GGG GAT GTG ATG CAT CTG TCC CAG AGT CCC AGC GTC 1104Arg Leu Ser Glu Gly Asp Val Met His Leu Ser Gln Ser Pro Ser Val
355 360 365AGT CAG CTA AGT GTC CTG AGT CTA AGT GGG GTC ATG CTG ACC GAT GTA 1152Ser Gln Leu Ser Val Leu Ser Leu Ser Gly Val Met Leu Thr Asp Val
370 375 380AGT CCC GAG CCC CTC CAA GCT CTG CTG GAG AGA GCC TCT GCC ACC CTC 1200Ser Pro Glu Pro Leu Gln Ala Leu Leu Glu Arg Ala Ser Ala Thr Leu385 390 395 400CAG GAC CTG GTC TTT GAT GAG TGT GGG ATC ACG GAT GAT CAG CTC CTT 1248Gln Asp Leu Val Phe Asp Glu Cys Gly Ile Thr Asp Asp Gln Leu Leu
405 410 415GCC CTC CTG CCT TCC CTG AGC CAC TGC TCC CAG CTT ACA ACC TTA AGC 1296Ala Leu Leu Pro Ser Leu Ser His Cys Ser Gln Leu Thr Thr Leu Ser
420 425 430TTC TAC GGG AAT TCC ATC TCC ATA TCT GCC TTG CAG AGT CTC CTG CAG 1344Phe Tyr Gly Asn Ser Ile Ser Ile Ser Ala Leu Gln Ser Leu Leu Gln
435 440 445CAC CTC ATC GGG CTG AGC AAT CTG ACC CAC GTG CTG TAT CCT GTC CCC 1392His Leu Ile Gly Leu Ser Asn Leu Thr His Val Leu Tyr Pro Val Pro
450 455 460CTG GAG AGT TAT GAG GAC ATC CAT GGT ACC CTC CAC CTG GAG AGG CTT 1440Leu Glu Ser Tyr Glu Asp Ile His Gly Thr Leu His Leu Glu Arg Leu465 470 475 480GCC TAT CTG CAT GCC AGG CTC AGG GAG TTG CTG TGT GAG TTG GGG CGG 1488Ala Tyr Leu His Ala Arg Leu Arg Glu Leu Leu Cys Glu Leu Gly Arg
485 490 495CCC AGC ATG GTC TGG CTT AGT GCA ACC CCT GTC CTC ACT GTG GGG ACA 1536Pro Ser Met Val Trp Leu Ser Ala Thr Pro Val Leu Thr Val Gly Thr
500 505 510GAA CCT TCT ATG ACC CGG 1554Glu Pro Ser Met Thr Arg
515
Claims (16)
1.组合物,包括:
(i)一种肿瘤排斥抗原前体或肿瘤排斥抗原,以及至少如下之一:
(ii)一种药学上可接受的佐剂,以及一种T或B细胞生长因子。
2.权利要求1的组合物,其中所说的肿瘤排斥抗原前体是一种MAGE蛋白。
3.权利要求1的组合物,其中所说的肿瘤排斥抗原前体是一种BAGE蛋白。
4.权利要求1的组合物,其中所说的肿瘤排斥抗原前体是一种GAGE蛋白。
5.权利要求1的组合物,其中所说的肿瘤排斥抗原是一种MAGE衍生蛋白。
6.权利要求5的组合物,其中所说的MAGE蛋白是MAGE-1,MAGE-2或MAGE-3。
7.权利要求6的组合物,其中所说的肿瘤排斥抗原由SEQ ID NO:1-SEQ ID NO:5中的一个组成。
8.权利要求1的组合物,其中所说的药学上可接受的佐剂是一种来源于皂树(Ouillajisaponaria)的基本上纯的皂苷。
9.权利要求8的组合物,其中所说的基本上纯的皂苷选自由QA-7,QA-21,QA-17和QA-18组成的一组。
10.权利要求1的组合物,其中所说的药学上可接受的佐剂是MTP-MF59。
11.在患者中刺激免疫应答的方法,包括将权利要求1的组合物给予所说患者,给药量应足以唤起针对所说的肿瘤排斥抗原前体或肿瘤排斥抗原的免疫应答。
12.权利要求11的方法,其中所说的免疫应答包括对所说的肿瘤排斥抗原和所说的肿瘤排斥抗原所结合的主要组织相容性复合物分子的复合物有特异性的T细胞的增殖作用。
13.权利要求11的方法,其中所说的T细胞是胞溶性T细胞。
14.权利要求11的方法,其中所说的免疫应答包括产生抗所说的肿瘤排斥抗原前体或肿瘤排斥抗原的抗体。
15.静脉注射形式的权利要求1的组合物。
16.脂质体形态的权利要求1的组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31596194A | 1994-09-30 | 1994-09-30 | |
US08/315,961 | 1994-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1159759A true CN1159759A (zh) | 1997-09-17 |
Family
ID=23226857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95195411A Pending CN1159759A (zh) | 1994-09-30 | 1995-09-27 | 含有肿瘤排斥抗原前体或肿瘤排斥抗原以及佐剂和/或生长因子的组合物 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0782453A1 (zh) |
JP (1) | JPH10511639A (zh) |
CN (1) | CN1159759A (zh) |
AU (1) | AU690371B2 (zh) |
CA (1) | CA2201327A1 (zh) |
WO (1) | WO1996010413A1 (zh) |
ZA (1) | ZA958229B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6328971B1 (en) * | 1993-01-22 | 2001-12-11 | Ludwig Institute For Cancer Research | MAGE-1 derived nona peptides, and compositions thereof |
US5997870A (en) * | 1994-06-03 | 1999-12-07 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B44 Molecules |
US20060029653A1 (en) | 1997-01-29 | 2006-02-09 | Cronk Peter J | Therapeutic delivery system |
AU8571598A (en) * | 1997-07-17 | 1999-02-10 | Ludwig Institute For Cancer Research | Cancer associated nucleic acids and polypeptides |
CZ298364B6 (cs) * | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
US6686147B1 (en) | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
US6809179B1 (en) | 1999-08-04 | 2004-10-26 | Boehringer Ingelheim International Gmbh | Tumor-associated antigen (R11) |
RU2009111263A (ru) | 2006-08-30 | 2010-10-10 | Дэвид Уилльям СМИТ (US) | Способ придания одноосевой или многоосевой жесткости экструдированным материалам, а также изделия, получаемые из них |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5462871A (en) * | 1992-08-31 | 1995-10-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode MAGE derived nonapeptides |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
-
1995
- 1995-09-27 JP JP8512031A patent/JPH10511639A/ja active Pending
- 1995-09-27 EP EP95938112A patent/EP0782453A1/en not_active Withdrawn
- 1995-09-27 CA CA002201327A patent/CA2201327A1/en not_active Abandoned
- 1995-09-27 AU AU38864/95A patent/AU690371B2/en not_active Ceased
- 1995-09-27 WO PCT/US1995/012463 patent/WO1996010413A1/en not_active Application Discontinuation
- 1995-09-27 CN CN95195411A patent/CN1159759A/zh active Pending
- 1995-09-29 ZA ZA958229A patent/ZA958229B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JPH10511639A (ja) | 1998-11-10 |
EP0782453A1 (en) | 1997-07-09 |
AU3886495A (en) | 1996-04-26 |
WO1996010413A1 (en) | 1996-04-11 |
CA2201327A1 (en) | 1996-04-11 |
AU690371B2 (en) | 1998-04-23 |
ZA958229B (en) | 1996-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI117555B (fi) | Kasvaimen hyljintäantigeenin esiasteet, kasvaimen hyljintäantigeenit ja niiden käytöt | |
US6599699B1 (en) | Methods for diagnosing a disorder by assaying for MAGE-3 | |
AU698310B2 (en) | Determination of cancerous conditions by mage gene expression | |
AU686314B2 (en) | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides | |
US20110236406A1 (en) | Immunogenic compositions comprising hmgb1 polypeptides | |
WO2007063903A1 (ja) | 新規ペプチド化合物 | |
WO2005045027A1 (ja) | Wt1由来のhla−dr結合性抗原ペプチド | |
US8258261B2 (en) | Induction of tumor immunity by variants of folate binding protein | |
US20150225456A1 (en) | Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies | |
US6821517B1 (en) | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells | |
US5925729A (en) | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof | |
CN1159759A (zh) | 含有肿瘤排斥抗原前体或肿瘤排斥抗原以及佐剂和/或生长因子的组合物 | |
CN1152251A (zh) | 编码由hla-a2提呈的肿瘤排斥抗原的分离的核酸分子 | |
US6498021B1 (en) | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-8 and uses thereof | |
AU664560B2 (en) | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof | |
IE84173B1 (en) | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof | |
WO2004022589A9 (fr) | Marqueur tumoral et ses applications | |
Hollingsworth | Sanderson et al. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) |